- Home
- Menu
- Enrollment
- Empanelment
- Administrators
- Gallery
- COVID
- Highend
- PMJAY
- Contact us
| Package Name | Category | A1 | A2 | A3 | A4 | A5 | A6 | S1 | S2 |
|---|---|---|---|---|---|---|---|---|---|
| CM0100 : BREAST CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-a : BREAST CANCER - combined regimen AC & T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-a-I : BREAST CANCER - Dose Dense AC (Adriamycin/Cyclophosphamide) ; (Day 1: Doxorubicin 60mg/m2 IV, Cyclophosphamide 600mg/m2 IV) ; Repeat cycle - every 14 days for 4 cycles; Followed by Paclitaxel for 4 cycles | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
| CM0100-a-II : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 14 days for 4 cycles | MEDICAL ONCOLOGY | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
| CM0100-b : BREAST CANCER - TC (Doectaxel & Cyclophosphamide) ; Day 1: Docetaxel 75mg/m2 IV, Cyclophosphamide 600mg/m2 IV ; Repeat cycle - every 21 days for 4 cycles | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0100-c : BREAST CANCER - CMF (Cyclophosphamide/Methotrexate/Fluorouracil) - (includes day 1 & day 8) ; Days 1-14: Cyclophosphamide 100mg/m2 orally ; Days 1 and 8: Methotrexate 40mg/m2 IV ; Days 1 and 8: 5-fluorouracil 600mg/m2 IV. ; Repeat cycle - every 28 days for 6 cycles | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
| CM0100-d : BREAST CANCER - EC (Epirubicin/Cyclophosphamide) ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 830mg/m2 IV. ; Repeat cycle - every 21 days for 8 cycles | MEDICAL ONCOLOGY | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 |
| CM0100-e : BREAST CANCER - FEC + T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-e-I : BREAST CANCER - FEC/CEF followed by T (Fluorouracil/Epirubicin/Cyclophosphamide) - followed by Docetaxel or followed by weekly Paclitaxel) ; Day 1: 5-fluorouracil 500mg/m2 IV ; Day 1: Epirubicin 100mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle every 21 days for 3 cycles | MEDICAL ONCOLOGY | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 |
| CM0100-e-II : BREAST CANCER - Docetaxel - (Preceeded by FEC/CEF ) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle - every 21 days for 3 cycles | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
| CM0100-e-III : BREAST CANCER - Paclitaxel - weekly - (Preceeded by FEC/CEF ) ; Paclitaxel 100mg/m2 IV ; Repeat cycle - once weekly for 8 weeks | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
| CM0100-f : BREAST CANCER - FAC + T | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-f-I : BREAST CANCER - FAC followed by T (Fluorouracil/Adriamycin/Cyclophosphamide) - followed by weekly Paclitaxel ; 5-fluorouracil 500mg/m2 IV Days 1 and 8 OR 1 and 4: ; Day 1: Doxorubicin 50mg/m2 IV ; Day 1: Cyclophosphamide 500mg/m2 IV. ; Repeat cycle - every 21 days for 6 cycles | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
| CM0100-f-II : BREAST CANCER - Paclitaxel - weekly - Preceeded by FAC ; Paclitaxel 80mg/m2 IV ; Repeat Cycle weekly for 12 weeks. | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
| CM0100-g : BREAST CANCER - TAC (Docetaxel/Adriamycin/Cyclophosphamide) ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
| CM0100-h : BREAST CANCER - AC followed by T + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-h-I : BREAST CANCER - AC - followed by Paclitaxel + Trastuzumab +/- Pertuzumab ; Day 1: Doxorubicin 60mg/m2 IV ; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle - every 21 days for 4 cycle | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
| CM0100-h-II : BREAST CANCER - Paclitaxel (Preceeded by AC) ; (To be choosen along with Trastuzumab package - CM0100-h-III or CM0100-h-IV or CM0100-h-V) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
| CM0100-h-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with Paclitaxel Cycle 1, 4, 7, 10 and standalone for the upto 1 year every 21 days) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-h-IV : BREAST CANCER - Trastuzumab 4mg (Followed by Trastuzumab 2mg subsequent weeks) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-h-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-h-II) ; Day 1: Trastuzumab 2mg/kg IV weekly Till one year from Day 1 of AC. ; (to be approved with Paclitaxel Cycles 2 - 12 and standalone for the upto 1 year every week) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
| CM0100-i : BREAST CANCER - TCH | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-i-I : BREAST CANCER - TC (Docetaxel/Carboplatin) ; (To be choosen along with Trastuzumab package - CM0100-i-II or CM0100-i-III or CM0100-i-IV) ; Day 1: Docetaxel 75mg/m2 IV; Carboplatin AUC 6mg per min/mL IV. ; every 21 days for 6 cycles | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
| CM0100-i-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with TC package CM0100-i-I) ; Trastuzumab 6mg/kg IV ; Repeat cycle every 21 days to complete 1 year. ; (to be approved with TC Cycle 1 to 6 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 18 weeks as standalone for the upto 1 year every 21 days) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-i-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with TC package CM0100-i-I) ; Day 1: Trastuzumab 4mg/kg IV ; (First dose - only to be approved with TC Cycle 1. Subsequent cycles - 2mg package only) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-i-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses - Weekly) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 17 weeeks may overlap with TC Cycles 2 - 6. To be followed by Trastuzumab (6mg) package upto 1 year | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
| CM0100-j : BREAST CANCER - AC followed by Docetaxel + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-j-I : BREAST CANCER - AC - followed by Docetaxel + Trastuzumab ; Day 1: Doxorubicin 60mg/m2 IV; Day 1: Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
| CM0100-j-II : BREAST CANCER - Docetaxel (preceeded by AC) + Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-j-III or CM0100-j-IV or CM0100-j-V) ; Day 1: Docetaxel 100mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
| CM0100-j-III : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel package CM0100-j-II) ; Day 1: Trastuzumab 6mg/kg IV ; Repeat every 21 days till 1 year ; (to be approved with Docetaxel Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) or from 13 th week after completion of 12 weeks of weekly Trastuzumab - upto 1 year every 21 days) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-j-IV : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel package CM0100-j-II) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel Cycle 1. Subsequent cycles - 2mg package only) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-j-V : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
| CM0100-k : BREAST CANCER - Docetaxel + Cyclophosphamide + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-k-I : BREAST CANCER - Docetaxel + Cyclophosphamide - with Trastuzumab ; (To be choosen along with Trastuzumab package - CM0100-k-II or CM0100-k-III or CM0100-k-IV) ; Day 1: Docetaxel 75mg/m2 IV; Cyclophosphamide 600mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
| CM0100-k-II : BREAST CANCER - Trastuzumab (6mg) ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Day 1: Trastuzumab 6mg/kg IV ; (to be approved with Docetaxel + Cyclophosphamide Cycle 1 to 4 and standalone for the upto 1 year every 21 days (or) after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-k-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Docetaxel + Cyclophosphamide package CM0100-k-I) ; Trastuzumab 4mg/kg IV ; (First dose - only to be approved with Docetaxel + Cyclophosphamide Cycle 1. Subsequent cycles - 2mg package only) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-k-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; Trastuzumab 2mg/kg IV ; (to be approved weekly for 11 weeeks may overlap with Docetaxel + Cyclophosphamide Cycles 2 - 4. To be followed by Trastuzumab (6mg) package upto 1 year) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
| CM0100-L : BREAST CANCER - Paclitaxel + Trastuzumab | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-L-I : BREAST CANCER - Paclitaxel - (with Trastuzumab) ; (To be choosen along with Trastuzumab package - CM0100-L-III or CM0100-L-IV) ; Paclitaxel 80mg/m2 IV. ; Repeat Cycle weekly for 12 weeks. | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
| CM0100-L-II : BREAST CANCER - Trastuzumab (6mg) ; trastuzumab 6mg/kg IV ; Repeat every 21 days ; (to be approved after completion of weekly trastuzumab for 12 weeks as standalone for the upto 1 year every 21 days) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-L-III : BREAST CANCER - Trastuzumab 4mg (First dose - only) - followed by 2mg ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Trastuzumab 4mg/kg IV with first dose of paclitaxel. ; (First dose - only to be approved with Paclitaxel Cycle 1. Subsequent cycles - 2mg package only) | MEDICAL ONCOLOGY | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 | 30500 |
| CM0100-L-IV : BREAST CANCER - Trastuzumab 2mg (Subsequent doses) ; (to be choosen along with Paclitaxel package CM0100-L-I) ; Day 1: Trastuzumab 2mg/kg IV weekly ; (to be approved with Paclitaxel Cycles 2 - 12. May be approved as standalone for the upto 1 year every week or Trastuzumab 6mg Package may be used once every 21 days upto 1 year) | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
| CM0100-M : BREAST CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0101 : BLADDER CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0101-a-I : BLADDER CANCER - DDMVAC ; Day 1: Methotrexate 30mg/m2 IV; Day 2: Vinblastine 3mg/m2 IV, doxorubicin 30mg/m2 IV, cisplatin 70mg/m2 IV; ; Repeat every 2 weeks for 3-4 cycles | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0101-a-II : BLADDER CANCER - Gemcitabine + cisplatin ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV; Day 2: Cisplatin 70mg/m2. ; Repeat every 4 weeks for 4 cycles. | MEDICAL ONCOLOGY | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 |
| CM0101-a-III : BLADDER CANCER - Cisplatin + methotrexate + vinblastine (CMV) ; Day 1: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV; Day 2: Cisplatin 100mg/m2 IV, leucovorin 15mg oral or IV every 6 hours for 4 doses; Day 8: Methotrexate 30mg/m2 IV, vinblastine 4mg/m2 IV Day 9: Leucovorin 15mg oral every 6 hours for 4 doses ; Repeat every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 | 4800 |
| CM0101-b : BLADDER CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0102 : LUNG CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0102-i : LUNG CANCER - Mesothelioma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0102-i-a : LUNG CANCER - Mesothelioma - Pemetrexed + cisplatin ; Day 1: Pemetrexed 500mg/m2 IV, cisplatin 75mg/m2 ; Repeat every 21 days up to 12 cycles. | MEDICAL ONCOLOGY | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 |
| CM0102-i-b : LUNG CANCER - Mesothelioma - Pemetrexed + carboplatin ; Day 1: Pemetrexed 500mg/m2 IV, carboplatin AUC 5mg/min/mL IV. ; Repeat every 21 days for a max of 9 cycles. | MEDICAL ONCOLOGY | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 |
| CM0102-i-c : LUNG CANCER - Mesothelioma - Cisplatin & Gemcitabine ; Day 1: Cisplatin 80-100mg/m2 IV ; Days 1, 8, and 15: Gemcitabine 1000-1250mg/m2 IV ; Repeat every 21 - 28 days for 6 cycles. | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
| CM0102-i-d : LUNG CANCER - Mesothelioma - Vinorelbine ; Vinorelbine 25-30mg/m2 (max 60mg) IV ; Repeat every week for 12 weeks. | MEDICAL ONCOLOGY | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 |
| CM0102-i-e : LUNG CANCER - Mesothelioma - Pemetrexed ; Day 1: Pemetrexed 500mg/m2 IV. ; Repeat every 21 days for 4 cycles (If First line) or Repeat every 21 days for 8 cycles (If Second line) | MEDICAL ONCOLOGY | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 |
| CM0102-i-f : LUNG CANCER - Mesothelioma - Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1250mg/m2 IV. ; Repeat every 28 days for a max of 10 cycles. | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
| CM0102-i-g : LUNG CANCER - Mesothelioma - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0102-ii : LUNG CANCER - NSCLC | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0102-ii-a : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (i) ; Days 1 and 8: Cisplatin 50mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 25mg/m2 IV ; (or) ; Day 1: Cisplatin 100mg/m2 IV and Days 1, 8, 15 and 22: Vinorelbine 30mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. | MEDICAL ONCOLOGY | 33600 | 33600 | 33600 | 33600 | 33600 | 33600 | 33600 | 33600 |
| CM0102-ii-b : LUNG CANCER - NSCLC - Cisplatin & Vinorelbine - (ii) ; Day 1: Cisplatin 75-80mg/m2 ; Days 1 and 8: Vinorelbine 25-30mg/m2. ; Repeat every 3 weeks for 4 cycles | MEDICAL ONCOLOGY | 17900 | 17900 | 17900 | 17900 | 17900 | 17900 | 17900 | 17900 |
| CM0102-ii-c : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 100mg/m2 IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles | MEDICAL ONCOLOGY | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 |
| CM0102-ii-d : LUNG CANCER - NSCLC - Cisplatin & Docetaxel ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
| CM0102-ii-e : LUNG CANCER - NSCLC - Cisplatin & Gemcitabine ; Day 1: Cisplatin 75mg/m2 IV ; Days 1 and 8: Gemcitabine 1,250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
| CM0102-ii-f : LUNG CANCER - NSCLC - Pemetrexed + cisplatin (for Non Squamous Cell CA) ; Day 1: Cisplatin 75mg/m2 IV, pemetrexed 500mg/m2 IV. ; Repeat every - 21 days for 4 cycles. | MEDICAL ONCOLOGY | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 | 14500 |
| CM0102-ii-g : LUNG CANCER - NSCLC - Paclitaxel/Carboplatin ; Day 1: Paclitaxel 200mg/m2 IV, carboplatin AUC 6mg per min/mL IV. ; Repeat cycle every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 |
| CM0102-ii-h : LUNG CANCER - NSCLC - Cisplatin & Etoposide ; Days 1, 8, 29 and 36: Cisplatin 50mg/m2 IV ; Days 1-5 and 29-33: Etoposide 50mg/m2 IV ; Concurrent thoracic radiotherapy 1.8Gy/day for 5 days/week (total dose, 61Gy). | MEDICAL ONCOLOGY | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 | 8500 |
| CM0102-ii-i : LUNG CANCER - NSCLC - Cisplatin & Vinblastine ; Days 1 and 29: Cisplatin 100mg/m2 IV ; Days 1, 8, 15, 22 and 29: Vinblastine 5mg/m2 IV ; concurrent thoracic radiotherapy (total dose, 60Gy). | MEDICAL ONCOLOGY | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 |
| CM0102-ii-j : LUNG CANCER - NSCLC - Carboplatin + Pemetrexed ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 |
| CM0102-ii-k : LUNG CANCER - NSCLC - Cisplatin + Pemetrexed ; Day 1: Cisplatin 75 mg/m2 IV. ; Day 1: Pemetrexed 500 mg/m2 IV ; with concurrent thoracic radiotherapy. ; Repeat every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 |
| CM0102-ii-l : LUNG CANCER - NSCLC - Paclitaxel + Carboplatin ; Paclitaxel 45mg/m2 IV + carboplatin AUC 2mg per min/mL IV ; with concurrent thoracic radiotherapy (total dose, 60Gy) ; Repeat weekly for 6 weeks | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
| CM0102-ii-m : LUNG CANCER - NSCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0102-iii : LUNG CANCER - SCLC | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0102-iii-a : LUNG CANCER - SCLC - Cisplatin & Etoposide ; Day 1: Cisplatin 60mg/m2 IV, Days 1-3: Etoposide 120mg/m2 IV. ; Repeat cycle every 3 weeks for at least 4 cycles. ;(OR) ; Day 1: Cisplatin 80mg/m2 IV, Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 4 weeks for 4-6 cycles. | MEDICAL ONCOLOGY | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 |
| CM0102-iii-b : LUNG CANCER - SCLC - Carboplatin & Etoposide ; Day 1: Carboplatin AUC 5-6mg per min/mL IV ; Days 1-3: Etoposide 100mg/m2 IV. ; Repeat cycle every 21 days or 28 days for 4 - 6 cycles | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0102-iii-c : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles. | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
| CM0102-iii-d : LUNG CANCER - SCLC - Cisplatin + Irinotecan ; Day 1 and 8: Cisplatin 30mg/m2 IV, irinotecan 65mg/m2 IV. ; Repeat cycle every 3 weeks for 4-6 cycles. | MEDICAL ONCOLOGY | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 | 5700 |
| CM0102-iii-e : LUNG CANCER - SCLC - Carboplatin & Irinotecan ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 50mg/m2 IV. ; Repeat cycle every 4 weeks for 4 cycles | MEDICAL ONCOLOGY | 7700 | 7700 | 7700 | 7700 | 7700 | 7700 | 7700 | 7700 |
| CM0102-iii-f : LUNG CANCER - SCLC - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) ; (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0103-i : ESOPHAGEAL CANCER - Neo Adjuvant | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0103-i-a : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV + carboplatin AUC 2mg/min/mL IV. ; Repeat weekly for 5 weeks | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
| CM0103-i-b : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV. | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
| CM0103-i-c : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5 and Days 22-26: 5-FU 800 mg/m2 IV ; Repeat every 21 days for 2 cycles | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
| CM0103-i-d : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil + Oxaliplatin + Leucovorin ; Day 1: Oxaliplatin 85mg/m2, leucovorin 200mg/m2 and 5-FU 400mg/m2 bolus, with 1,600mg/m2 infusion; ; Repeat every 14 days for 6 cycles | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
| CM0103-i-e : ESOPHAGEAL CANCER - Neo Adjuvant - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
| CM0103-i-f : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV | MEDICAL ONCOLOGY | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 |
| CM0103-i-g : ESOPHAGEAL CANCER - Neo Adjuvant - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks. | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
| CM0103-i-h : ESOPHAGEAL CANCER - Neo Adjuvant - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV, cisplatin 30mg/m2 IV. | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
| CM0103-i-i : ESOPHAGEAL CANCER - Neo Adjuvant - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV infusion. ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
| CM0103-i-j : ESOPHAGEAL CANCER - Neo Adjuvant - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 |
| CM0103-i-k : ESOPHAGEAL CANCER - Neo Adjuvant - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0103-ii : ESOPHAGEAL CANCER - Peri-Operative | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0103-ii-a : ESOPHAGEAL CANCER - Peri-Operative - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV continuous infusion once daily; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively | MEDICAL ONCOLOGY | 16700 | 16700 | 16700 | 16700 | 16700 | 16700 | 16700 | 16700 |
| CM0103-ii-b : ESOPHAGEAL CANCER - Peri-Operative - EOF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
| CM0103-ii-c : ESOPHAGEAL CANCER - Peri-Operative - EOC (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | MEDICAL ONCOLOGY | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 |
| CM0103-ii-d : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV ; Repeat cycle every 28 days for 2-4 cycles | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
| CM0103-ii-e : ESOPHAGEAL CANCER - Peri-Operative - Fluorouracil & Cisplatin ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cyclesCycled every 21 days for 2 cycles | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
| CM0103-ii-f : ESOPHAGEAL CANCER - Peri-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0103-iii : ESOPHAGEAL CANCER - Post-Operative | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0103-iii-a : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (i) ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV, followed by 4 weeks break and CCRT ; RT Days 1-4 and 23-25: 5-FU 400mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV followed by one month Break and ; Days 1-5: 5-FU 425mg/m2/day IV and leucovorin 20mg/m2/day IV. | MEDICAL ONCOLOGY | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 |
| CM0103-iii-b : ESOPHAGEAL CANCER - Post-Operative - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 200mg/m2 IV, 5-FU 400mg/m2 IV push and 5-FU 600mg/m2 infusion | MEDICAL ONCOLOGY | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 |
| CM0103-iii-c : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily; ; Repeat every 28 days; 1 cycle before and 2 cycles after chemoradiation | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
| CM0103-iii-d : ESOPHAGEAL CANCER - Post-Operative - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily, ; once weekly for 5 weeks. | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
| CM0103-iii-e : ESOPHAGEAL CANCER - Post-Operative - FluorouracilDays 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV continuous infusion over 24 hours daily, ; once weekly for 5 weeks.once weekly for 5 weeks. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0103-iii-f : ESOPHAGEAL CANCER - Post-Operative - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0103-iv : ESOPHAGEAL CANCER - Definitive | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0103-iv-a : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1,000mg/m2 IV | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
| CM0103-iv-b : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV daily ; Days 1-5: 5-FU 800 mg/m2 IV continuous infusion over 24 hours. ; Cycled every 21 days for 2 cycles | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
| CM0103-iv-c : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Oxaliplatin ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day continuous IV infusion. | MEDICAL ONCOLOGY | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 |
| CM0103-iv-d : ESOPHAGEAL CANCER - Definitive - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily ; Repeat cycle weekly for 5 weeks | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
| CM0103-iv-e : ESOPHAGEAL CANCER - Definitive - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
| CM0103-iv-f : ESOPHAGEAL CANCER - Definitive - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV and carboplatin 2mg/min/mL IV ; Repeat weekly for 5 weeks. | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
| CM0103-iv-g : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (i) ; Days 1 and 22: Docetaxel 60mg/m2 IV ; Days 1 and 22: Cisplatin 60-80mg/m2 IV given for 1 cycle | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
| CM0103-iv-h : ESOPHAGEAL CANCER - Definitive - Cisplatin with Docetaxel (ii) ; Day 1: Docetaxel 20-30mg/m2 IV ; Day 1: Cisplatin 20-30mg/m2 IV ; Repeat weekly for 5 weeks | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
| CM0103-iv-i : ESOPHAGEAL CANCER - Definitive - Cisplatin with Paclitaxel ; Days 1, 8, 15, and 22: Paclitaxel 60mg/m2 IV ; Day 1: Cisplatin 75mg/m2 IV given for 1 cycle. | MEDICAL ONCOLOGY | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 | 13100 |
| CM0103-iv-j : ESOPHAGEAL CANCER - Definitive - Irinotecan & Cisplatin ; Days 1, 8, 22, and 29: Irinotecan 65mg/m2 IV ; Days 1, 8, 22, and 29: Cisplatin 30mg/m2 IV. | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
| CM0103-iv-k : ESOPHAGEAL CANCER - Definitive - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45mg/m2 IV ; Days 1-5: 5-FU 300mg/m2/day IV ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
| CM0103-iv-l : ESOPHAGEAL CANCER - Definitive - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 PO twice daily. ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 | 12200 |
| CM0103-iv-m : ESOPHAGEAL CANCER - Definitive - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0104 : GASTRIC CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0104-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0104-i-a : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 50mg/m2 IV, carboplatin AUC 2mg/min/mL IV. ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
| CM0104-i-b : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (i) ; Days 1 and 29: Cisplatin 75-100mg/m2 IV ; Days 1-4 and 29-32: 5-FU 750-1000mg/m2/day IV | MEDICAL ONCOLOGY | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 | 12000 |
| CM0104-i-c : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Cisplatin (ii) ; Days 1-5: Cisplatin 15mg/m2 IV once daily, 5-FU 800mg/m2/day IV ; Repeat cycle every 21 days for 2 cycles. | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
| CM0104-i-d : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (i)Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-33: 5-FU 180mg/m2/day IV. | MEDICAL ONCOLOGY | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 | 25800 |
| CM0104-i-e : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Oxaliplatin (ii)Day 1: Oxaliplatin 85mg/m2 and leucovorin 400mg/m2 followed by 5-FU 400mg/m2 bolus, then 800mg/m2 24-hour continuous infusion over days 1 and 2; the first 3 cycles were delivered during radiotherapy (RT), the other 3 after RT; 6 bimonthly (14 days) cycles. | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
| CM0104-i-f : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Cisplatin + capecitabine ; Day 1: Cisplatin 30mg/m2 IV ; Days 1-5: Capecitabine 800mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
| CM0104-i-g : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Oxaliplatin + capecitabine ; Days 1, 15, and 29: Oxaliplatin 85mg/m2 IV ; Days 1-5: Capecitabine 625mg/m2 orally twice daily for 5 weeks | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
| CM0104-i-h : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Fluorouracil & Paclitaxel ; Day 1: Paclitaxel 45-50mg/m2 IV weekly ; Days 1-5: 5-FU 300mg/m2 IV ; Repeat cycle weekly for 5 weeks | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
| CM0104-i-i : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Paclitaxel + capecitabine ; Day 1: Paclitaxel 45-50mg/m2 IV ; Days 1-5: Capecitabine 625-825mg/m2 orally twice daily. ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
| CM0104-i-j : GASTRIC CANCER - Preoperative Chemoradiation (esophagogastric junction and gastric cardia) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0104-ii : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0104-ii-a : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF (Epirubicin/Cisplatin/Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV, cisplatin 60mg/m2 IV ; Days 1-21: 5-FU 200mg/m2/day IV ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively | MEDICAL ONCOLOGY | 16700 | 16700 | 16700 | 16700 | 16700 | 16700 | 16700 | 16700 |
| CM0104-ii-b : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - EOF (Epirubicin/ oxaliplatin /Fluorouracil) ; Day 1: Epirubicin 50mg/m2 IV; oxaliplatin 130mg/m2 IV ; Days 1-21: 5-FU 200mg/m2 IV; ; Repeat every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | MEDICAL ONCOLOGY | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 | 18700 |
| CM0104-ii-c : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - epirubicin + cisplatin + capecitabine ; Day 1: Epirubicin 50mg/m2 IV + cisplatin 60mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively. | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
| CM0104-ii-d : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - ECF modification (epirubicin + oxaliplatin + capecitabine) ; Day 1: Epirubicin 50mg/m2 IV + oxaliplatin 130mg/m2 IV ; Days 1-21: Capecitabine 625mg/m2 orally twice daily. ; Repeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperativelyRepeat cycle every 21 days for 3 cycles preoperatively and 3 cycles postoperatively | MEDICAL ONCOLOGY | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 |
| CM0104-ii-e : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Fluorouracil & Cisplatin ; Day 1: Cisplatin 75-80mg/m2 IV ; Days 1-5: 5-FU 800mg/m2 IV ; Repeat cycle every 28 days for 2-3 cycles preoperatively and 3-4 cycles postoperatively for a total of 6 cycles. | MEDICAL ONCOLOGY | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 | 6900 |
| CM0104-ii-f : GASTRIC CANCER - Perioperative Chemotherapy (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0104-iii : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0104-iii-a : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (i) ; Cycles 1, 3, and 4 (before and after radiation) Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2/day IV ; Repeat cycle every 28 days. ; Cycle 2 (with radiation) Days 1-4 and 31-33: Leucovorin 20mg/m2 IVP ; Days 1-4: 5-FU 400mg/m2/day IVP. ; Repeat cycle every 35 days | MEDICAL ONCOLOGY | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 | 25400 |
| CM0104-iii-b : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil + Leucovorin (ii) ; Days 1, 2, 15, and 16: Leucovorin 400mg/m2 IV, 5-FU 400mg/m2 IV and 5-FU 1200mg/m2 infusion; ; 1 cycle before and 2 cycles after chemoradiation. ; Repeat cycle every 28 daysRepeat cycle every 28 days | MEDICAL ONCOLOGY | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 | 14900 |
| CM0104-iii-c : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (i) ; Days 1-14: Capecitabine 750-1000mg/m2 orally twice daily. ; Repeat cycle every 28 days; 1 cycle before and 2 cycles after chemoradiation. | MEDICAL ONCOLOGY | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 | 3100 |
| CM0104-iii-d : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Capecitabine (ii) ; Days 1-5 OR Days 1-7: Capecitabine 625-825mg/m2 orally twice daily; weekly for 5 weeks. | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
| CM0104-iii-e : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Fluorouracil ; Days 1-5 OR Days 1-7: 5-FU 200-250mg/m2 IV; ; weekly for 5 weeks. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0104-iii-f : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Cisplatin + capecitabine ; Day 1: Cisplatin 60mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 6 cycles. | MEDICAL ONCOLOGY | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 | 4000 |
| CM0104-iii-h : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Oxaliplatin + capecitabine ; Day 1: Oxaliplatin 130mg/m2 IV. ; Days 1-14: Capecitabine 1000mg/m2 orally twice daily ; Repeat cycle every 21 days for 8 cycles.Repeat cycle every 21 days for 8 cycles. | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0104-iii-i : GASTRIC CANCER - Postoperative Chemoradiation (including esophagogastric junction) - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0105-i : COLORECTAL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0105-i-a : COLORECTAL CARCINOMA - FOLFOX (Stage - III) - (Oxaliplatin, Leucovorin, 5-FU) ; Day 1: Oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV , 5-FU 400mg/m2 IV, followed by 5-FU 1,200mg/m2/day IV x 2 days (total 2,400mg/m2) over 46-48-hour continuous infusion. ; Repeat cycle every 2 weeks- upto 12 cycles | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
| CM0105-i-b : COLORECTAL CARCINOMA - CAPEOX (Stage - III) (Oxaliplatin, Capecitabine) ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Days 1-14: Capecitabine 1,000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 6 months | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0105-i-c : COLORECTAL CARCINOMA - FLOX (Stage - III) (5-FU, leucovorin, oxaliplatin) ; 5-FU 500mg/m2 IV bolus weekly x 6, leucovorin 500mg/m2 IV weekly x 6, each ; oxaliplatin 85mg/m2 IV on weeks 1, 3, and 5 ; 8-week cycle x 3 cycles ; | MEDICAL ONCOLOGY | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 |
| CM0105-i-d : COLORECTAL CARCINOMA - Capecitabine ; Capecitabine 1,250mg/m2 - BD / TDS D 1-14 ; every 3 weeks * 24 weeks | MEDICAL ONCOLOGY | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 |
| CM0105-i-e : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (i) ; Leucovorin 500mg/m2 weekly x 6 weeks, ; 5-FU 500mg/m2 weekly x 6 weeks. ; Repeat cycle every 8 weeks for 4 cycles. | MEDICAL ONCOLOGY | 23700 | 23700 | 23700 | 23700 | 23700 | 23700 | 23700 | 23700 |
| CM0105-i-f : COLORECTAL CARCINOMA - Fluorouracil + Leucovorin (ii)Simplified biweekly infusion. ; Leucovorin 400mg/m2 IV, 5-FU bolus 400mg/m2 and then 1,200mg/m2/day x 2 days (total 2,400mg/m2 over 46-48 hours) ; Repeat cycle every 2 weeks for 6 cycles. | MEDICAL ONCOLOGY | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 | 5200 |
| CM0105-i-g : COLORECTAL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0105-ii : COLORECTAL CARCINOMA - Concurrent | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0105-ii-a : COLORECTAL CARCINOMA - Concurrent - 5FU - with XRT ; Days 1-5 OR 1-7: 5-FU 225mg/m2 IV ; with External beam radiotherapy | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0105-ii-b : COLORECTAL CARCINOMA - Concurrent - Fluorouracil + Leucovorin - with XRT ; Days 1-4: 5-FU 400mg/m2 IV + leucovorin 20mg/m2 IV. ; Repeat cycle during weeks 1 and 5 of XRT. | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
| CM0105-ii-c : COLORECTAL CARCINOMA - Concurrent - Capecitabine - with XRT ; Capecitabine Tablet 825mg / m2 twice daily on Days 1-5 ; Repeat cycle weekly for 5 weeks. | MEDICAL ONCOLOGY | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 |
| CM0105-ii-d : COLORECTAL CARCINOMA - Concurrent - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0106-106 : OSTEOSARCOMA/ BONE TUMORS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0106-i-a : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Cisplatin + doxorubicin ; Days 1-3: Doxorubicin 25mg/m2/day IV, ; Day 1: Cisplatin 100mg/m2 IV ; Repeat cycle every 3 weeks for 6 cycles | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
| CM0106-i-b-1 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - PRE OPERATIVE ; Days 1 and 28: Methotrexate 8g/m2 IV ; Days 7-9 and 34-36: Cisplatin 120mg/m2 by infusion for 72 hours. ; Days 9 and 36: Doxorubicin 60mg/m2 IV | MEDICAL ONCOLOGY | 24200 | 24200 | 24200 | 24200 | 24200 | 24200 | 24200 | 24200 |
| CM0106-i-b-2 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS < 90% ; Days 1, 48, 96, and 144: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 69, and 117: Methotrexate 8g/m2 IV ; Days 27, 75, and 123: Cisplatin 120mg/m2 by infusion for 72 hours. | MEDICAL ONCOLOGY | 40100 | 40100 | 40100 | 40100 | 40100 | 40100 | 40100 | 40100 |
| CM0106-i-b-3 : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - MAP (high-dose methotrexate + cisplatin + doxorubicin) - POST OPERATIVE NECROSIS > 90%Postoperative Chemotherapy (Necrosis <90%) ; Days 1, 69, 138, and 207: Doxorubicin 45mg/m2/day for 2 consecutive days ; Days 21, 90, and 159: Ifosfamide 2g/m2/day IV for 5 consecutive days + mesna ; Days 42, 111, and 180: Methotrexate 8g/m2 IV ; Days 48, 117, and 186: Etoposide 120mg/m2/day for 3 days. | MEDICAL ONCOLOGY | 59100 | 59100 | 59100 | 59100 | 59100 | 59100 | 59100 | 59100 |
| CM0106-i-c : Doxorubicin + cisplatin + ifosfamide + high-dose methotrexate (surgery to be done also) | MEDICAL ONCOLOGY | 111505 | 111505 | 111505 | 111505 | 111505 | 111505 | 111505 | 111505 |
| CM0106-i-d : OSTEOSARCOMA/ BONE TUMORS / Dedifferentiated chondrosarcoma - Ifosfamide + cisplatin + epirubicin ; Day 1: Epirubicin 90mg/m2 IV, cisplatin 100mg/m2 IV ; Days 2-4: Ifosfamide 2.0g/m2 with mesna ; Repeat cycle every 21 days. (3 cycles preoperatively and 3 cycles postoperatively). | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
| CM0106-ii : Other bone tumors - Chordroma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0106-ii-a : Other bone tumors - Chordroma - Imatinib ; Imatinib 800 mg once daily | MEDICAL ONCOLOGY | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 |
| CM0106-ii-b : Other bone tumors - Chordroma - Imatinib + cisplatin ; Imatinib 400mg OD + cisplatin 25mg/m2 weekly. | MEDICAL ONCOLOGY | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 | 4500 |
| CM0106-ii-c : Other bone tumors - Chordroma - Imatinib + sirolimus ; Imatinib 400mg OD + sirolimus 2mg OD | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0106-ii-d : Other bone tumors - Chordroma - Erlotinib ; Erlotinib 150mg OD | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
| CM0106-ii-e : Other bone tumors - Chordroma - Sunitinib ; Sunitinib 37.5mg OD | MEDICAL ONCOLOGY | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 |
| CM0106-iii :Other bone tumors - Giant Cell Tumor of Bone | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0106-iii-a :Other bone tumors - Giant Cell Tumor of Bone - Denosumab ; Denosumab 120mg subcutaneous on Week 1,2 and 3 of a 4 week cycle | MEDICAL ONCOLOGY | 56000 | 56000 | 56000 | 56000 | 56000 | 56000 | 56000 | 56000 |
| CM0106-iii-b :Other bone tumors - Giant Cell Tumor of Bone - Interferon alfa ; interferon alfa- 2a thrice weekly | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
| CM0106-iii-c :Other bone tumors - Giant Cell Tumor of Bone - Peginterferon ; Peginterferon alfa-2a 1.0mcg/kg SQ injection weekly. | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
| CM0106-iv : Other bone tumors - Mesenchymal Chordosarcoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0106-iv-a : VAC and IE cycles | MEDICAL ONCOLOGY | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 | 6420 |
| CM0106-iv-b : Other bone tumors - Mesenchymal Chordosarcoma VAIA ; Day 1: Vincristine 1.5mg/m2 IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 3 weeks. | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
| CM0106-v : Other bone tumors - Mesenchymal Chordosarcoma Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0107 : WILMS TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0107-a : WILMS TUMOR - Vincristine & Actinomycin D ; Dactinomycin 45mcg/kg - week - 0, 3, 6,9,12,15,18 ; Vincristine 1.5 mg/m2 - week - 1,2,3,4,5,6,7,8,9,10,12,15,18 | MEDICAL ONCOLOGY | 19400 | 19400 | 19400 | 19400 | 19400 | 19400 | 19400 | 19400 |
| CM0107-b : WILMS TUMOR - Dactinomycin, Vincristine & Adriamycin ; Dactinomycin 1.35 mg /m2 - week - 0, 6, 12, 18,24 ; Adriyamycin 30-45 mg /m2- week - 3, 9, 15, 21 ; Vincristine 2mg max- week - 1,2,3,4,5,6,7,8,9,10,12,15,18,21,24 | MEDICAL ONCOLOGY | 23200 | 23200 | 23200 | 23200 | 23200 | 23200 | 23200 | 23200 |
| CM0107-c : WILMS TUMOR - Adriamycin, Cyclophosphamide, Etoposide, Vincristine ; Cyclophosphamide 440mg/m2/day - week 3, 9, 15, 21 for 5 days, week - 6,12,18,24 for 3 days ; Adriyamycin 30-45mg /m2- week -0, 6, 12, 18,24 ; Vincristine 2mg (max)- week - 1,2,4,5,6,7,8,10,11, 12,13,18,24 ; Etoposide 100mg /m2- week - 3,9,15,21 | MEDICAL ONCOLOGY | 53700 | 53700 | 53700 | 53700 | 53700 | 53700 | 53700 | 53700 |
| CM0107-d : WILMS TUMOR - Cyclophosphamide, Etoposide, Carboplatin ; Cyclophosphamide 440mg/m2/day - week 6,15,24 *5 days / week ; Carboplatin 500mg/m2 - week - 0,3,9,12,18,21 *2 days / week ; Etoposide 100mg/m2 - week - 0,3,9,12,18,21 *5 days / week | MEDICAL ONCOLOGY | 84500 | 84500 | 84500 | 84500 | 84500 | 84500 | 84500 | 84500 |
| CM0107-e : WILMS TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0108 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0108-a : HEPATOBLASTOMA- OPERABLE - PLADO - Cisplatin + Doxorubicin ; cisplatin (PLA) (80mg/m2 / iv), doxorubicin (DO) (30 mg/m2 IV ; Every 21 days for 6 cycles | MEDICAL ONCOLOGY | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 |
| CM0108-b : HEPATOBLASTOMA- OPERABLE - Cisplatin + Vincristine +5FU ; cisplatin (90 mg/m2), vincristine (1.5mg/m2), 5-FU(5-Flurouracil- 600 mg/m2) ; Every 21 days for 6 cycles | MEDICAL ONCOLOGY | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 |
| CM0108-c : HEPATOBLASTOMA- OPERABLE - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0109 : HEPATOCELLULAR CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0109-a : HEPATOCELLULAR CARCINOMA - Sorafenib ; Sorafenib 400 mg PO BID | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
| CM0109-b : HEPATOCELLULAR CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0110A : Neuroblastoma ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
| CM0110B : Neuroblastoma ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300mg/m2 ; ADRIAMYCIN 60mg/m2 ; VINCRISTINE 1.5mg/m2 | MEDICAL ONCOLOGY | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 | 7100 |
| CM0110C : Neuroblastoma ALL STAGES - Cisplatin & Etoposide ; Days 1-5 : Cisplatin - 20mg/m2 ; Days 1-5 : Etoposide - 70 mg/m2 | MEDICAL ONCOLOGY | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 | 4900 |
| CM0110D : Neuroblastoma ALL STAGES - Carboplatin & Etoposide ; Days 1-2 : Carboplatin - 500mg/m2 ; Days 1-5: Etoposide 100mg/m2 | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0110E : Neuroblastoma ALL STAGES - For Stage IV Palliative Chemotherapy only | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0110F : Neuroblastoma ALL STAGES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0111 : RETINOBLASTOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0111-a : RETINOBLASTOMA - Melphalan - Intra-arterial ; Melphalan - 3-7.5mg - Intra-arterial | MEDICAL ONCOLOGY | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 | 9700 |
| CM0111-b : RETINOBLASTOMA - Carboplatin - Intra-arterial ; Carboplatin 15-30 mg - Intra-arterial | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
| CM0111-c : RETINOBLASTOMA - Topotecan - Intra-arterial ; Topotecan 0.15-1.5 mg - Intra-arterial | MEDICAL ONCOLOGY | 9900 | 9900 | 9900 | 9900 | 9900 | 9900 | 9900 | 9900 |
| CM0111-d : RETINOBLASTOMA - Methotrexate - Intra-arterial ; Methotrexate 6-12 mg - Intra-arterial | MEDICAL ONCOLOGY | 8600 | 8600 | 8600 | 8600 | 8600 | 8600 | 8600 | 8600 |
| CM0111-e : RETINOBLASTOMA - Carboplatin - Peri Ocular ; Carboplatin 20mg/m2 - Peri Ocular | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
| CM0111-f : RETINOBLASTOMA - Topotecan - Peri Ocular ; Topotecan 0.09 - 0.27 - Peri Ocular | MEDICAL ONCOLOGY | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 |
| CM0111-g : RETINOBLASTOMA - Melphalan - Intra-vitreal ; Melphalan 20-30 mcg / 0.1cc - Intra-vitreal | MEDICAL ONCOLOGY | 270 | 270 | 270 | 270 | 270 | 270 | 270 | 270 |
| CM0111-h : RETINOBLASTOMA - Carboplatin - Intra-vitreal ; Carboplatin 3-6mcg / 0.05cc - Intra-vitreal | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
| CM0111-i : RETINOBLASTOMA - Methotrexate - Intra-vitreal ; Methotrexate 400mcg/0.1cc - Intra-vitreal | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
| CM0111-j : RETINOBLASTOMA - Carboplatin + Etoposide + Vincristine ; Carboplatin 560mg/m2 ; Etoposide 150mg/m2 ; Vincristine 1.5mg/m2 | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
| CM0111-k : RETINOBLASTOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0112 : HISTIOCYTOSIS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0112-a : HISTIOCYTOSIS - Prednisolone and Vinblastine - 1; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 | MEDICAL ONCOLOGY | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 | 6100 |
| CM0112-b : HISTIOCYTOSIS - Prednisolone and Vinblastine - 2; Prednisolone and Vinblastine - 1 ; Prednisolone - 6 weeks oral ; Vinblastine 1,2,3,4,5,6 | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
| CM0112-c : HISTIOCYTOSIS - Prednisolone and Vinblastine - continuation; Prednisolone and Vinblastine - continuation after either course 1 or both 1 & 2 ; Prednisolone - 5 days a week oral ; Vinblastine -IV ; repeat every 3 weeks till 1 year | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0112-d : HISTIOCYTOSIS - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0113 : RHABDOMYOSARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0113-a : RHABDOMYOSARCOMA - VAC (Vincristine + Dactinomycin + Cyclophosphamide + Mesna ) ; Day -1 - Vincristine 1.5 mg /m2 IV (2 mg max), Doxorubicin 75 mg /m2 IV , cyclophosphamide 1200 mg /m2 IV + mesna ; Repeat at 21 day intervals for 4-6 cycles | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0113-b : RHABDOMYOSARCOMA - IVA (Vincristine + Dactinomycin + Ifosfamide + Mesna ) ; Day 1,2 - Ifosfamide IV 3 g/m2 + mesna ; Day 1 - Vincristine IV 1.5 mg/m2 (max 2 mg), Actinomycin-D IV 1.5 mg/m2 (max 2 mg) ; Repeat at 21 day intervals for 6 cycles | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
| CM0113-c : RHABDOMYOSARCOMA - IVAD (Vincristine + Doxorubicin + Ifosfamide + Mesna ) ; Days 1 and 2 - Ifosfamide 3 g/m2 + Mesna, Doxorubicin 30mg/m2 ; Day 1 - vincristine 1.5 mg/m2, Actinomycin-D 1.5 mg/m2 ; Repeat at 21 day intervals for 6 cycles | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
| CM0113-d : RHABDOMYOSARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0114 : EWINGS SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0114-i : EWINGS SARCOMA - Induction Treatment I | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0114-i-a : EWINGS SARCOMA - Induction Treatment - VIDE ; Day 1:Vincristine 1.5mg/m2(max 2mg) IV ; Days 1-3:Doxorubicin 20mg/m2 IV, ifosfamide 3g/m2IV, mesna continuous IV, etoposide 150mg/m2 IV ; Repeat cycle every 3 weeks for up to 6 cycles | MEDICAL ONCOLOGY | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 | 8300 |
| CM0114-i-b : EWINGS SARCOMA - Induction Treatment - VAC/IE ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0114-i-c : EWINGS SARCOMA - Induction Treatment - VAIA - 4 day Regimen ; Day 1:Vincristine 1.5mg/m2IV ; Days 1-3: Ifosfamide 2,000mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 4 cycles, then local therapy, followed by 10 additional cycles of VAIA for High risk and ; 10 additional cycles of VAIA or 10 cycles of VACA for standard-risk patients | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
| CM0114-i-d : EWINGS SARCOMA - Induction Treatment - VAIA - 24 day Regimen ; Days 1, 8, 15, and 22: Vincristine 1.5mg/m2 IV ; Days 1, 2, 22, 23, 43, and 44 : Ifosfamide 3,000mg/m2 IV + mesna ; Days 1, 2, 43, and 44 : Doxorubicin 30mg/m2 IV ; Days 22, 23, and 24: Dactinomycin 0.5mg/m2 IV ; After completion of one 9-week cycle, local therapy followed by 3 additional cycles. | MEDICAL ONCOLOGY | 17700 | 17700 | 17700 | 17700 | 17700 | 17700 | 17700 | 17700 |
| CM0114-ii : EWINGS SARCOMA - Maintenance Treatment | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0114-ii-a : EWINGS SARCOMA - Maintenance Treatment - Etoposide/Ifosfamide ; Days 1-5: Ifosfamide 1,800mg/m2/day IV + mesna ; Days 1-5: Etoposide 100mg/m2/day IV. | MEDICAL ONCOLOGY | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 | 8200 |
| CM0114-iii : EWINGS SARCOMA - Maintenance Treatment - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0115 : PALLIATIVE CHEMOTHERAPY (Any Regimen)- Maximum Payable | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0116 : CERVICAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0116-a : CERVICAL CANCER - CISPLATIN ; Cisplatin 40mg/m2 IV once weekly for up to 6 cycles | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0116-b : CERVICAL CANCER - Cisplatin & 5FU with RT ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 IV over 96 hours ; Repeat cycle every 3 weeks for 3 | MEDICAL ONCOLOGY | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 |
| CM0116-c : CERVICAL CANCER - Cisplatin & 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV | MEDICAL ONCOLOGY | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 | 8900 |
| CM0116-d : CERVICAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0117 : VULVAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0117-a : VULVAL CANCER - Cisplatin ; Day 1 : 40 mg/m 2 IV | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0117-b : VULVAL CANCER - Cisplatin + 5FU ; Days 1-5 of radiotherapy: Cisplatin 75mg/m2 IV, 5-FU 4,000mg/m2 ; Repeat cycle every 3 weeks - total 3 cycles | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
| CM0117-c : VULVAL CANCER - 5-FU + Mitomycin ; 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day continuous IV infusion ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), | MEDICAL ONCOLOGY | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 |
| CM0117-d : VULVAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0118 : VAGINAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0118-a : VAGINAL CANCER - Cisplatin ; Cisplatin 75mg/m2 ; once weekly for up to 6 doses | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0118-b : VAGINAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0119 : OVARIAN CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0119-a : OVARIAN CANCER - Paclitaxel + Cisplatin ; Day 1: Paclitaxel 135mg/m2 continuous IV ; Day 2: Cisplatin 75-100mg/m2 ; Day 8: Paclitaxel 60mg/m2 ; Repeat every 3 weeks for 6 cycles. | MEDICAL ONCOLOGY | 8800 | 8800 | 8800 | 8800 | 8800 | 8800 | 8800 | 8800 |
| CM0119-b : OVARIAN CANCER - Paclitaxel + Carboplatin ; Day 1: Paclitaxel 175mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL IV ; Repeat every 3 weeks for 6 cycles | MEDICAL ONCOLOGY | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
| CM0119-c : OVARIAN CANCER - Docetaxel + Carboplatin ; Day 1: Docetaxel 60-75mg/m2 IV, Carboplatin AUC 5-6 mg/min/mL ; Repeat every 3 weeks for 6 cycles | MEDICAL ONCOLOGY | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 |
| CM0119-d : OVARIAN CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0120 : ENDOMETRIAL CANCER (Palliative Chemotherapy only) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0121 : OVARY- GERM CELL TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0121-a : OVARY- GERM CELL TUMOR - BEP (Bleomycin + Etoposide + Cisplatin) ; Days 1,8,15 : Bleomycin 30 units/wk IV, Etoposide 100 mg/m 2/day IV ; Days 1-5 : Cisplatin 20 mg/m 2/day IV ; Repeat every 21 days 3-4 cycles | MEDICAL ONCOLOGY | 10800 | 10800 | 10800 | 10800 | 10800 | 10800 | 10800 | 10800 |
| CM0121-b : OVARY- GERM CELL TUMOR - EP ( Etoposide + Carboplatin) ; Day 1 : Carboplatin 400 mg/m 2 IV on days 1-3 ; Repeat every 28 days for three cycles | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0121-c : OVARY- GERM CELL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0122 : GESTATIONAL TROPHOBLAST DISEASES | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0122-a : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (5 days regimen) ; Days 1-5: MTX 0.4 mg/kg/day IV or IM for 5 days, not to exceed 25 mg/day ; Repeat cycle every 14 days | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0122-b : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate (8-day alternating regimen) ; Days 1, 3, 5, and 7 : MTX 1 mg/kg IM, ; Days 2, 4, 6, and 8 : Folinic acid 15 mg ; Repeat cycle every 14 days | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
| CM0122-c : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate + Folinic Acid ; Day 1 : MTX 100 mg/m 2 IVP, then 200 mg/m 2 infusion ; Day 2 : Folinic acid 15 mg IM/PO q12h for 4 doses ; Repeat cycle every 18 days | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
| CM0122-d : GESTATIONAL TROPHOBLAST DISEASES - Methotrexate - Weekly ; MTX 30-50 mg/m 2 IM weekly | MEDICAL ONCOLOGY | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 | 1300 |
| CM0122-e : GESTATIONAL TROPHOBLAST DISEASES - Act-D ; Act-D 10-13 mcg/kg or 0.5-mg flat dose IV qd for 5d ; Repeat cycle every 14 days | MEDICAL ONCOLOGY | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 | 7800 |
| CM0122-f : GESTATIONAL TROPHOBLAST DISEASES - Actinomycin ; Actinomycin 1.25 mg/m 2 IV ; Repeat every 2 weeks | MEDICAL ONCOLOGY | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 | 2200 |
| CM0122-g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (complete) ; Day 1 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, MTX - 300 mg/m2 IV ; Day 2 : Act-D - 0.5 mg IV, Etoposide - 100 mg/m2 IV, Leucovorin - 15 mg PO/IM q12h 4 doses ; Day 8 : Vincristine - 0.8 mg/m2 IV, Cyclophosphamide - 600 mg/m2 IV ; Repeat cycle every 14 days | MEDICAL ONCOLOGY | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 | 6400 |
| CM0122-h : GESTATIONAL TROPHOBLAST DISEASES - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0123 : TESTICULAR CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0123-a : TESTICULAR CANCER - EP ; Days 1-5: Etoposide 100mg/m2, cisplatin 20mg/m2 ; Repeat cycle every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
| CM0123-b : TESTICULAR CANCER - BEP ; Days 1-5: Cisplatin 20mg/m2, etoposide 100mg/m2 ; Days 1, 8, and 15 OR Days 2, 9, or 16: Bleomycin 30 units IV ; Repeat cycle every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0123-c : TESTICULAR CANCER - VIP ; Day 1 (before ifosfamide): Mesna 120mg/m2 IV ; Days 1-5: Etoposide 75mg/m2 IV, mesna 1,200mg/m2 IV, ifosfamide 1,200mg/m2 IV + cisplatin 20mg/m2. ; Repeat cycle every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 | 6300 |
| CM0123-d : TESTICULAR CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0124 : PROSTATE CANCERPROSTATE CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0124-a : PROSTATE CANCER - Docetaxel + prednisone ; Day 1: Docetaxel 75mg/m2 IV, prednisone 5mg orally twice daily. ; once every 3 weeks, Repeat for up to 10 cycles if tolerated | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
| CM0124-b : PROSTATE CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0125 : FEBRILE NEUTROPENIA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0125-a : FEBRILE NEUTROPENIA - First-line monotherapy ; Piperacillin-tazobactam 4.5 g ; Cefepime 2 g ; Meropenem 1 g ; Imipenem-cilastatin 500 mg | MEDICAL ONCOLOGY | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 |
| CM0125-b : FEBRILE NEUTROPENIA - Second-line dual therapy ; Piperacillin-tazobactam 4.5 g IV plus an aminoglycoside ; Meropenem 1 g IV plus an aminoglycoside ; Imipenem-cilastatin 500 mg IV plus an aminoglycoside | MEDICAL ONCOLOGY | 19500 | 19500 | 19500 | 19500 | 19500 | 19500 | 19500 | 19500 |
| CM0125-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0126 : THYROID CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0126-a : THYROID CANCER - sorafenib ; sorafenib 400 mg PO BID | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
| CM0126-b : THYROID CANCER - sunitinib ; sunitinib 50 mg | MEDICAL ONCOLOGY | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 | 28500 |
| CM0126-c : THYROID CANCER - pazopanib | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
| CM0126-d : THYROID CANCER - Doxorubicin ; Doxorubicin 60 mg/m2 as monotherapy or in combination with cisplatin 40 mg/m2 | MEDICAL ONCOLOGY | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 |
| CM0126-e : THYROID CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0127 : THYMOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0127-a : THYMOMA - CAP ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 50mg/m2 IV, cyclophosphamide 500mg/m2 IV. ; Repeat every 21 days for a max of 8 cycles. | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
| CM0127-b : THYMOMA - CAPP ; Day 1: Cyclophosphamide 500mg/m2 IV ; Days 1-3: Cisplatin 30mg/m2 IV ; Days 1-3: Doxorubicin 20mg/m2 ; Days 1-5: Prednisone 100mg. ; Repeat every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
| CM0127-c : THYMOMA - ADOC ; Day 1: Cisplatin 50mg/m2 IV, doxorubicin 40mg/m2 IV ; Day 3: Vincristine 0.6mg/m2 IV ; Day 4: Cyclophosphamide 700mg/m2 IV. ; Repeat every 3 weeks for 5 cycles. | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
| CM0127-d : THYMOMA - PE ; Day 1: Cisplatin 60mg/m2 IV ; Days 1-3: Etoposide 120mg/m2 IV ; Repeat every 3 weeks for a max of 8 cycles. | MEDICAL ONCOLOGY | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 |
| CM0127-e : THYMOMA - VIP ; Days 1-4: Etoposide 75mg/m2 IV, ifosfamide 1.2g/m2 IV, cisplatin 20mg/m2 IV. ; Repeat every 3 weeks for 4 cycles | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
| CM0127-f : THYMOMA - Carboplatin+paclitaxel ; Day 1: Paclitaxel 225mg/m2 IV, carboplatin AUC = 6 IV ; Repeat every 3 weeks for a max of 6 cycles. | MEDICAL ONCOLOGY | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 | 9300 |
| CM0127-g : THYMOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0128 : BRAIN CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-i : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-i-a : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Combination PCV (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally. ; Days 8-21: Procarbazine 60mg/m2 orally once daily. ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0128-i-b : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (7 weeks) ; Days 1-49: Temozolomide 75mg/m2 orally. ; Repeat cycle every 11 weeks (7 weeks on/4 weeks off) for 6 cycles. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0128-i-c : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide monthly 5-day course ; Temozolomide monthly 5-day courses at doses of 180 - 200mg/m2/day | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0128-i-d : BRAIN CARCINOMA - Systemic Therapy for Adult Low-Grade Infiltrative Supratentorial Astrocytoma/Oligodendroglioma - Temozolomide (3 weeks) ; Days 1-21: Temozolomide 75mg/m2/day orally. ; Repeat cycle every 28 days. | MEDICAL ONCOLOGY | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 |
| CM0128-ii : BRAIN CARCINOMA - Systemic Therapy for Anaplastic GliomasSystemic Therapy for Anaplastic Gliomas | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-ii-a : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Temozolomide monthly 5-day course ; Days 1-5: Temozolomide 200mg/m2/day orally. ; Repeat cycle every 4 weeks until disease progression or for up to 24 cycles. | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0128-ii-b : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV with deferred RT (lomustine + procarbazine + vincristine) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0128-ii-c : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-ii-d : Adjuvant Temozolomide | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0128-ii-e : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - PCV for 1p19q co-deleted (with Radiotherapy) ; Day 1: Lomustine 110mg/m2 orally ; Days 8-21: Procarbazine 60mg/m2 orally once daily ; Days 8 and 29: Vincristine 1.4mg/m2 (maximum 2mg) IV. ; Repeat every 6 weeks. for 6 cycles | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0128-iii : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-iii-a : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
| CM0128-iii-b : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Adjuvant Temozolomide (preceeded by Concurrent temozolzmide) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days for 6 cycles. | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0128-iii-c : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (post RT) ; Days 1-5: Temozolomide 150-200mg/m2/day orally for 5 days. ; Repeat cycle every 28 days | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0128-iii-d : BRAIN CARCINOMA - Systemic Therapy for Glioblastoma - Temozolomide (200mg) with standard RT ; Days 1-5: Temozolomide 200mg/m2, orally | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0128-iv : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-iv-a : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + lomustine ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; ; During Cranio-spinal RT | MEDICAL ONCOLOGY | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 |
| CM0128-iv-b : BRAIN CARCINOMA - Systemic Therapy for Adult Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumor (PNET) - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV. | MEDICAL ONCOLOGY | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 | 5500 |
| CM0128-v : BRAIN CARCINOMA - Primary CNS LymphomaPrimary CNS Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-v-a : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapyHigh dose methotrexate combined with the following plus radiation therapy | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-v-a-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + Cytarabine ; Day 1: MTX 3.5g/m2 ; Days 2-3: Cytarabine 2g/m2 IV twice a day. | MEDICAL ONCOLOGY | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 |
| CM0128-v-a-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose Methotrexate + leucovorin + Ifosfamide + mesna ; Day 1: MTX 4gm/m2 IV, ; Days 2-5: leucovorin 20-25mg IV (upto 40mg) ; Days 3-5: Ifosfamide 1.5gm/m2 IV + mesna 400mg IV | MEDICAL ONCOLOGY | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 | 9500 |
| CM0128-v-b : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate combined with the following plus radiation therapy High dose methotrexate (MTX 2.5-4.0mg/m2) + chemotherapy monoclonal antibody | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-v-b-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + MTX + vincristine +procarbazine ; Day 1: Rituximab 500mg/m2 IV ; Day 2: MTX 3.5mg/m2 IV plus vincristine 1.4mg/m2 ; Procarbazine 100mg/m2/day administered for 7 days with odd-numbered cycles | MEDICAL ONCOLOGY | 41900 | 41900 | 41900 | 41900 | 41900 | 41900 | 41900 | 41900 |
| CM0128-v-c : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate (MTX 8.0mg/m2) + chemotherapy +/- monoclonal antibody High dose methotrexate (MTX 8.0mg/m2) + chemotherapy monoclonal antibody | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-v-c-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Induction ; MTX 8g/m2 IV ; Repeat every 2 weeks until complete response achieved or max of 8 cycles reached. ; | MEDICAL ONCOLOGY | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 |
| CM0128-v-c-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Consolidation ; MTX 8g/m2 IV administered ; Repeat every 2 weeks for 2 cycles. | MEDICAL ONCOLOGY | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 |
| CM0128-v-c-3-i : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (Cycles 1-4) ; Day 1: MTX 8g/m2 IV, Rituximab 375mg/m2 IV. ; Repeat every 4 weeks for 4 cycles | MEDICAL ONCOLOGY | 32400 | 32400 | 32400 | 32400 | 32400 | 32400 | 32400 | 32400 |
| CM0128-v-c-3-ii : BRAIN CARCINOMA - Primary CNS Lymphoma - High dose methotrexate Maintanance (cycles 5-11) ; MTX 8g/m2 IV administered every 4 weeks for 11 cycles. ; Repeat cycle every 4 weeks for 4 cycles | MEDICAL ONCOLOGY | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 |
| CM0128-v-d : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-v-d-1 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - Induction ; Day 1: Rituximab 375mg/m2 IV, followed by ; Days 1-5: Temozolomide 150-200mg/m2 orally daily, after rituximab infusion. ; Repeat cycle every 4 weeks for 4 cycles. | MEDICAL ONCOLOGY | 26600 | 26600 | 26600 | 26600 | 26600 | 26600 | 26600 | 26600 |
| CM0128-v-d-2 : BRAIN CARCINOMA - Primary CNS Lymphoma - Rituximab + Temozolomide regimen - MaintananceDays 1-5: Temozolomide 150-200mg/m2 orally daily. ; Repeat cycle every 4 weeks for 8 cycles. | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
| CM0128-v-e : BRAIN CARCINOMA - Meningioma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0128-v-e-1 : BRAIN CARCINOMA - Meningioma - Interferon-alfaInterferon-alfa ; alpha-IFN 106 units/m2 SC every other day for 4 weeks. ; Repeat cycle every 4 weeks. ; | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0128-v-e-2 : BRAIN CARCINOMA - Meningioma -Somatostatin analog ; Sandostatin LAR Depot 10-30mg IM ; Repeat every 4 weeks. ; | MEDICAL ONCOLOGY | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 | 5400 |
| CM0128-v-e-3 : BRAIN CARCINOMA - Meningioma - Sunitinib ; Days 1-28: Sunitinib 50mg orally daily. ; Repeat cycle every 42 days. | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
| CM0129 : HEAD AND NECK CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-i : HEAD AND NECK CANCER - Squamous Cell Cancers | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-i-a : HEAD AND NECK CANCER - HIgh Dose Cisplatin ; Cisplatin 100mg/m2 IV + concurrent radiotherapy; Repeat cycle every 3 weeks for 3 cycles | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
| CM0129-i-b : HEAD AND NECK CANCER - Carboplatin + infusional 5-FU ; Days 1-4: 5-FU 600mg/m2/day as continuous IV I, carboplatin 70mg/m2/day IV ; Repeat every 3 weeks for 3 cycles (given concurrently with radiotherapy). | MEDICAL ONCOLOGY | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 | 4700 |
| CM0129-i-c : HEAD AND NECK CANCER - 5-FU + hydroxyurea ; Day 1: Hydroxyurea 1,000mg orally every 12 hours (11 doses/cycle), 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy | MEDICAL ONCOLOGY | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 |
| CM0129-i-d : HEAD AND NECK CANCER - Cisplatin + paclitaxel ; Day 1: Paclitaxel 30mg/m2 IV (every Monday), ; Day 2: Cisplatin 20mg/m2 IV (every Tuesday). ; Repeat cycle every week for 7 cycles, with Concurrent radiotherapy | MEDICAL ONCOLOGY | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 |
| CM0129-i-e : HEAD AND NECK CANCER - Cisplatin + infusional 5-FU ; Day 1: Cisplatin 60mg/m2 over ; Days 1-5: 5-FU 800mg/m2/day ; Repeat every other week for 7 cycles. with Concurrent radiotherapy | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
| CM0129-i-f : HEAD AND NECK CANCER - Carboplatin + paclitaxel ; Day 1: Paclitaxel 40-45mg/m2, carboplatin 100mg/m2 ; Repeat cycle every week for 8 cycles, with Concurrent radiotherapy | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
| CM0129-i-g : HEAD AND NECK CANCER - Weekly cisplatin ; Cisplatin 40mg/m2 IV per week | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0129-i-h : HEAD AND NECK CANCER - Cisplatin (For high risk oropharyngeal carcinoma) ; Days 1, 22, and 43: Cisplatin 100mg/m2 IV + radiotherapy. | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
| CM0129-i-i : HEAD AND NECK CANCER - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV, ; Days 1-5: 5-FU 750mg/m2/day IV. ; Repeat every 3 weeks for up to 4 cycles. | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
| CM0129-i-j : HEAD AND NECK CANCER - Paclitaxel + cisplatin+ infusional 5-FU ; Day 1: Paclitaxel 175mg/m2 ; Day 2: Cisplatin 100mg/m2 ; Day 2-6: 5-FU 500mg/m2/day IV ; Repeat every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 |
| CM0129-ii : HEAD AND NECK CANCER - Nasopharynx Cancer | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-ii-a : Nasopharynx Cancer - Concurrent Cisplatin followed by concurrent Cisplatin +5FUC ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-ii-a-1 : Nasopharynx Cancer - Concurrent Cisplatin (followed by concurrent Cisplatin +5FU) ; Day 1: Cisplatin 100mg/m2 IV; plus radiotherapy. ; Repeat cycle every 3 weeks for 3 cycles; followed by concurrent Cisplatin +5FU | MEDICAL ONCOLOGY | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 | 2000 |
| CM0129-ii-a-2 : Nasopharynx Cancer - concurrent Cisplatin +5FU - Preceeded by (Concurrent Cisplatin 3 cycles) ; Days 1-4: Cisplatin 80mg/m2/day, 5-FU 1,000mg/m2/day IV ; Repeat cycle every 4 weeks for 3 cycles | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
| CM0129-ii-b : Nasopharynx Cancer - Concurrent Carboplatin followed by concurrent Carboplatin +5FU | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-ii-b-1 : Nasopharynx Cancer - Concurrent Carboplatin - (followed by concurrent Carboplatin +5FU) ; Day 1: Carboplatin AUC 6mg/min/mL IV. ; Repeat cycle every 3 weeks for 3 cycles; | MEDICAL ONCOLOGY | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 | 4300 |
| CM0129-ii-b-2 : Nasopharynx Cancer - concurrent Carboplatin +5FU - Preceeded by (Concurrent Carboplatin ) ; Day 1: Carboplatin AUC 5mg/min/mL IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 | 13500 |
| CM0129-ii-c : Nasopharynx Cancer - Concurrent Cisplatin ; Cisplatin 40mg/m2 ; Repeat weekly for 7 cycles | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0129-ii-d : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU followed by Cisplatin ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-ii-d-1 : Nasopharynx Cancer - Docetaxel + cisplatin + 5-FU - followed by Cisplatin after 3 cycles ; Day 1: Docetaxel 70mg/m2 IV, cisplatin 75mg/m2 IV ; Days 1-4: 5-FU 1,000mg/m2/day IV ; Repeat every week for 3 cycles | MEDICAL ONCOLOGY | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 |
| CM0129-ii-d-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 3 cycles of Docetaxel + 5-FU ; Day 1: Cisplatin 100mg/m2; ; Repeat every 3 weeks, Till radiation | MEDICAL ONCOLOGY | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 |
| CM0129-ii-e : Nasopharynx Cancer - Docetaxel + cisplatin | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0129-ii-e-1 : Nasopharynx Cancer - Docetaxel + cisplatin - followed by Cisplatin after 2 cycles ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV ; Repeat every 3 weeks for two cycles | MEDICAL ONCOLOGY | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 |
| CM0129-ii-e-2 : Nasopharynx Cancer - Cisplatin - weekly - Preceded by 2 cycles of Docetaxel + cisplatin ; Cisplatin 40mg/m2 IV ; weekly concurrent with radiotherapy. | MEDICAL ONCOLOGY | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 | 2300 |
| CM0129-ii-f : Nasopharynx Cancer - Cisplatin + 5-FU ; Day 1: Cisplatin 100mg/m2/day IV. ; Days 1-4: 5-FU 1,000mg/m2/day continuous IV infusion for 4 days. ; Repeat cycle every 3 weeks for a minimum of 6 cycles | MEDICAL ONCOLOGY | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 |
| CM0129-iii : HEAD AND NECK CANCER (or) Nasopharynx Cancer - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0130 : RENAL CELL CARCINOMARENAL CELL CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0130-a : Pazopanib | MEDICAL ONCOLOGY | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 | 19000 |
| CM0130-b : Sunitinib | MEDICAL ONCOLOGY | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 | 29000 |
| CM0130-c : Sorafenib | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
| CM0130-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0131 : UNKNOWN PRIMARYUNKNOWN PRIMARY | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0131-i : UNKNOWN PRIMARY - Adenocarcinoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0131-i-a : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin + etoposide ; Day 1: Paclitaxel 200 mg/m 2 IV, carboplatin AUC 6 ; Days 1-10: etoposide 50 mg PO alternating with 100 mg daily ; Repeat every 21days for 2-3 cycles; restage, can be treated upto 8 cycles | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
| CM0131-i-b : UNKNOWN PRIMARY - Adenocarcinoma - Paclitaxel + carboplatin ; Day 1: Paclitaxel 200 mg/m 2, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
| CM0131-i-c : UNKNOWN PRIMARY - Adenocarcinoma - Docetaxel + carboplatin ; Day 1: Docetaxel 65mg/m2 IV, carboplatin AUC 6 ; Repeat cycle every 3 weeks, Maximum 8 cycles. | MEDICAL ONCOLOGY | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 | 3800 |
| CM0131-i-d : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + cisplatin ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat cycle every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
| CM0131-i-e : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + docetaxel ; Day 1 and 8: Gemcitabine 1000mg/m2 IV over 30 minutes ; Day 8: Docetaxel 75mg/m2 IV ; Repeat cycle every 3 weeks for a maximum of 6 cycles | MEDICAL ONCOLOGY | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 | 5800 |
| CM0131-i-f : UNKNOWN PRIMARY - Adenocarcinoma - Gemcitabine + irinotecan ; Days 1 and 8: Irinotecan 100mg/m2 IV, gemcitabine 1000mg/m2 IV. ; Repeat cycle every 3 weeks for 6 cycles.restage every 2-3 cycles | MEDICAL ONCOLOGY | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 | 5600 |
| CM0131-ii : UNKNOWN PRIMARY - Squamous cell carcinoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0131-ii-a : UNKNOWN PRIMARY - Squamous cell carcinoma - Paclitaxel + cisplatin + 5-FU ; Paclitaxel 175 mg/m 2 IV, ; Day 2: cisplatin 100 mg/m 2 IV, ; Day 5-FU (5-fluorouracil) 500 mg/m 2/day IV ; Repeat every 21d | MEDICAL ONCOLOGY | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 |
| CM0131-ii-b : UNKNOWN PRIMARY - Squamous cell carcinoma - Docetaxel + cisplatin + 5-FU ; Day 1: Docetaxel 75mg/m2 IV, cisplatin 75mg/m2 IV. ; Days 1-5: 5-FU 750mg/m2/day IV ; Repeat cycle every 3 weeks for 3 cycles. | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
| CM0131-iii : UNKNOWN PRIMARY - Neuroendocrine tumors | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0131-iii-b : UNKNOWN PRIMARY - Neuroendocrine tumors - Etoposide + cisplatin ; Days 1-3: Etoposide 100 mg/m 2 ; Days 2-3: cisplatin 45 mg/m 2 IV ; Repeat every 28 days | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
| CM0131-iv : UNKNOWN PRIMARY - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0132 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0132-a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Gemcitabine + cisplatin ; Days 1 and 8: Cisplatin 25mg/m2 IV, gemcitabine 1,000mg/m2 IV ; Repeat every 21 days for 4 cycles, re-evaluate and continue an additional 4 cycles if warranted | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
| CM0132-b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV | MEDICAL ONCOLOGY | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 | 4100 |
| CM0132-c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Capecitabine ; Capecitabine oral ; Repeat every 21 days | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
| CM0132-d : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0133 : PANCREAS CARCINOMAPANCREAS CARCINOMA - | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0133-i : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced ; | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0133-i-a : PANCREAS CARCINOMA - Patients with resectable pancreatic cancer - Locally Advanced Gemcitabine ; Days 1, 8, and 15: Gemcitabine 1,000mg/m2 IV ; Repeat every 4 weeks for six cycles | MEDICAL ONCOLOGY | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 | 6600 |
| CM0133-ii : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0133-ii-a : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - 5-FU + Leucovorin ; Days 1-5: Leucovorin 20mg/m2 IV, 5-FU 425mg/m2 IV ; Repeat cycle every 4 weeks | MEDICAL ONCOLOGY | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 | 5000 |
| CM0133-ii-b : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Gemcitabine & 5FU ; Prior to chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1, 8 and 15: Gemcitabine 1,000mg/m2 IV; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 4 weeks for 3 months. | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
| CM0133-ii-c : PANCREAS CARCINOMA - Adjuvant chemotherapy and chemoradiation - Continuous infusion 5-FU (with Radiation) ; Prior to chemoradiation: ; Days 1-21: 5-FU 250mg/m2/day continuous IV infusion; initiate 1-2 weeks prior to chemoradiation (50.4Gy + 5-FU 250mg/m2/day). ; After chemoradiation: ; Days 1-28: 5-FU 250mg/m2/day continuous IV infusion; initiate 3-5 weeks following chemoradiation. ; Repeat cycle every 6 weeks for 3 months. | MEDICAL ONCOLOGY | 20700 | 20700 | 20700 | 20700 | 20700 | 20700 | 20700 | 20700 |
| CM0133-iii : PANCREAS CARCINOMA - Neoadjuvant therapy - Neoadjuvant therapy | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0133-iii-a : PANCREAS CARCINOMA - Neoadjuvant therapy - CapecitabineCapecitabine ; Capecitabine ; Repeat cycle every 3 weeks for up to 52 weeks. | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
| CM0133-iv : PANCREAS CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0134 : PERI AMPULLARY CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0134-a : PERI AMPULLARY CARCINOMA - 5-FU ; Fluorouracil 425 mg/m2 administered on days 1 to 5 and 29-33 | MEDICAL ONCOLOGY | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 | 5300 |
| CM0134-b : PERI AMPULLARY CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0135 : NEURO ENDOCRINE CARCINOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0135-a : NEURO ENDOCRINE CARCINOMA - All NECs are covered under Organ Cancers. If uncovered - Unlisted only. | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0135-b : NEURO ENDOCRINE CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0136 : SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0136-i : SARCOMA - Gastrointestinal Stromal Tumor - GIST | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0136-i-a : SARCOMA - Gastrointestinal Stromal Tumor - GIST - Imatinib ; Imatinib 400mg orally once daily to twice daily | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
| CM0136-ii : SARCOMA - SOFT TISSUE SARCOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0136-ii-a : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + dacarbazine (AD) ; Days 1-4: Doxorubicin 60mg/m2 + dacarbazine 750mg/m2 ; Repeat cycle every 3 weeks | MEDICAL ONCOLOGY | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 | 11500 |
| CM0136-ii-b : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin + ifosfamide + mesna ; Days 1 and 2: Doxorubicin 30mg/m2/day IV, ifosfamide 3,750mg/m2/day IV, mesna 750mg/m2 IV ; Repeat cycle every 3 weeks | MEDICAL ONCOLOGY | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 |
| CM0136-ii-c : SARCOMA - SOFT TISSUE SARCOMA - Mesna + doxorubicin + ifosfamide + dacarbazine (MAID) ; Days 1-3: Doxorubicin 20mg/m2/day, ifosfamide 2,500mg/m2/day, dacarbazine 300mg/m2/day IV ; Days 1-4: Mesna 2,500mg/m2/day IV for 84 to 96 hours. ; Repeat cycle every 3 weeks. | MEDICAL ONCOLOGY | 10700 | 10700 | 10700 | 10700 | 10700 | 10700 | 10700 | 10700 |
| CM0136-ii-d : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide + epirubicin + mesna ; Days 1 and 2: Epirubicin 60mg/m2/day IV ; Days 1-5: Ifosfamide 1.8g/m2/day IV + mesna. ; Repeat cycle every 3 weeks for 5 cycles. | MEDICAL ONCOLOGY | 12800 | 12800 | 12800 | 12800 | 12800 | 12800 | 12800 | 12800 |
| CM0136-ii-e : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + docetaxel ; Days 1 and 8: Gemcitabine 900mg/m2 IV ; Day 8: Docetaxel 100mg/m2 IV. ; Repeat cycle every 3 weeks | MEDICAL ONCOLOGY | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 | 5100 |
| CM0136-ii-f : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + vinorelbine ; Days 1 and 8: Vinorelbine 25mg/m2 IV, gemcitabine 800mg/m2 IV ; Repeat cycle every 3 weeks | MEDICAL ONCOLOGY | 14700 | 14700 | 14700 | 14700 | 14700 | 14700 | 14700 | 14700 |
| CM0136-ii-g : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine + dacarbazine ; Day 1: Gemcitabine 1,800mg/m2 IV + dacarbazine 500mg/m2 IV. ; Repeat cycle ever 2 weeks for a total of 12 cycles; | MEDICAL ONCOLOGY | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 | 3300 |
| CM0136-ii-h : SARCOMA - SOFT TISSUE SARCOMA - Doxorubicin ; Doxorubicin 60-75mg/m2 IV ; once every 3 weeks | MEDICAL ONCOLOGY | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 | 2900 |
| CM0136-ii-i : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Days 1-3: Ifosfamide 2,000-3,000mg/m2/day IV for 3 to 4 days + mesna ; Repeat every 3 weeks. | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0136-ii-j : SARCOMA - SOFT TISSUE SARCOMA - Ifosfamide ; Day 1: Ifosfamide 5,000mg/m2 + mesna 5,000mg/m2 IV ; Day 2: mesna 400-600mg/m2 IV ; Ifosfamide, mesna ; Repeat every 3 weeks | MEDICAL ONCOLOGY | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 | 1900 |
| CM0136-ii-k : SARCOMA - SOFT TISSUE SARCOMA - Epirubicin ; Epirubicin 160mg/m2 IV ; Repeat every 3 weeks | MEDICAL ONCOLOGY | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 | 5900 |
| CM0136-ii-l : SARCOMA - SOFT TISSUE SARCOMA - Gemcitabine ; Days 1 and 8: Gemcitabine 1,200mg/m2 IV ; Repeat cycle every 3 weeks. | MEDICAL ONCOLOGY | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 | 3600 |
| CM0136-ii-m : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (i) ; Dacarbazine 250mg/m2/day IV for 5 days ; Repeat every 3 weeks. | MEDICAL ONCOLOGY | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 | 6200 |
| CM0136-ii-n : SARCOMA - SOFT TISSUE SARCOMA - Dacarbazine (ii) ; Dacarbazine 800-1,000mg/m2 IV ; Repeat every 3 weeks. | MEDICAL ONCOLOGY | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 | 2400 |
| CM0136-ii-o : SARCOMA - SOFT TISSUE SARCOMA - Liposomal doxorubicin ; Liposomal doxorubicin 30-50mg/m2 IV ; Repeat every 4 weeks. | MEDICAL ONCOLOGY | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 | 7900 |
| CM0136-ii-p : SARCOMA - SOFT TISSUE SARCOMA - Temozolomide ; Temozolomide 200mg/m2 orally twice daily for 5 days, followed by 9 doses of 90mg/m2 orally ; Repeat every 4 weeks | MEDICAL ONCOLOGY | 4200 | 4200 | 4200 | 4200 | 4200 | 4200 | 4200 | 4200 |
| CM0136-iii : SARCOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0137 : PRIMITIVE NEURO ECTODERMAL TUMOR | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0137-a : PRIMITIVE NEURO ECTODERMAL TUMOR - Weekly vincristine ; vincristine 1.5mg/m2 IV, max 2mg ; for 5 to 6 weeks | MEDICAL ONCOLOGY | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 | 1700 |
| CM0137-b : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + lomustine ; During craniospinal radiotherapy (RT) ; Day 1: Lomustine 75mg/m2 orally ; Day 2: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV bolus, max 2mg bolus; up to max 8 doses | MEDICAL ONCOLOGY | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 | 4400 |
| CM0137-c : PRIMITIVE NEURO ECTODERMAL TUMOR - Vincristine + cisplatin + cyclophosphamide ; Day 1: Cisplatin 75mg/m2 IV ; Days 2, 8 and 15: Vincristine 1.5mg/m2 IV, max 2mg ; Days 22, 23: Cyclophosphamide 1,000mg/m2 IV | MEDICAL ONCOLOGY | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 | 7600 |
| CM0137-d : PRIMITIVE NEURO ECTODERMAL TUMOR - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0137-vi : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0138 : MELANOMA - No primary regimens only RT. For advanced unresectable and metastatic disease - Pallitive Chemotherapy | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0139 : ANAL CANAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0139-a : ANAL CANAL CANCER - 5-FU + Mitomycin ; Days 1-4 and 29-32: 5-FU 1,000mg/m2/day IV ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus (maximum 20mg per course), with Concurrent radiotherapy | MEDICAL ONCOLOGY | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 | 11400 |
| CM0139-b : ANAL CANAL CANCER - Capecitabine + Mitomycin (i) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Days 1 and 29: Mitomycin 10mg/m2 IV bolus, with Concurrent radiotherapy. | MEDICAL ONCOLOGY | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 | 8100 |
| CM0139-c : ANAL CANAL CANCER - Capecitabine + Mitomycin (ii) ; Days 1-5: Capecitabine 825mg/m2 orally twice daily weekly for 6 weeks, ; Day 1: Mitomycin 12mg/m2 IV bolus, with Concurrent radiotherapy | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
| CM0139-d : ANAL CANAL CANCER - Cisplatin + 5-FU ; Days 1-5: 5-FU 1,000mg/m2/day IV ; Day 2: Cisplatin 100mg/m2 IV ; Repeat cycle every 4 weeks, with Concurrent radiotherapy | MEDICAL ONCOLOGY | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 | 6700 |
| CM0139-e : ANAL CANAL CANCER - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A : All Leukemia ( Chemotheraphy) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-I : Chronic Myeloid Leukemia (CML) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-I-i-a : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
| CM0952A-I-i-b : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
| CM0952A-I-ii : Blast phase-Lymphoid ALL Type Induction + TKI | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-I-ii-a : Induction | MEDICAL ONCOLOGY | 12840 | 12840 | 12840 | 12840 | 12840 | 12840 | 12840 | 12840 |
| CM0952A-I-ii-b : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
| CM0952A-I-ii-c : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
| CM0952A-I-iii : Blast phase-myeloid AML Type Induction + TKI | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-I-iii-a : Daunorubicin (90mg/m2)+ Cytarabine | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
| CM0952A-I-iii-b : Daunorubicin + Cytarabine + Cladribine | MEDICAL ONCOLOGY | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 |
| CM0952A-I-iii-c : Daunorubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 |
| CM0952A-I-iii-d : Daunorubicin (90mg) + Cytarabine | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
| CM0952A-I-iii-e : Idarubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 |
| CM0952A-I-iii-f : Idarubicin + Cytarabine | MEDICAL ONCOLOGY | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 |
| CM0952A-I-iii-g : mitoxantrone + Cytarabine | MEDICAL ONCOLOGY | 10820 | 10820 | 10820 | 10820 | 10820 | 10820 | 10820 | 10820 |
| CM0952A-I-iii-h : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
| CM0952A-I-iii-i : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
| CM0952A-I-iii-ii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-I-iii-iii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-II : Acute Myeloid Leukemia (AML) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-II-a : Daunorubicin + Cytarabine 1 | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
| CM0952A-II-b : Idarubicin + Cytarabine | MEDICAL ONCOLOGY | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 |
| CM0952A-II-c : Daunorubicin + Cytarabine 2 | MEDICAL ONCOLOGY | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 | 10365 |
| CM0952A-II-d : Daunorubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 | 16725 |
| CM0952A-II-e : Idarubicin + Cytarabine (High Dose) | MEDICAL ONCOLOGY | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 | 29600 |
| CM0952A-II-f : Daunorubicin (90mg) + Cytarabine | MEDICAL ONCOLOGY | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 | 12320 |
| CM0952A-II-g : idarubicin + Cytarabine | MEDICAL ONCOLOGY | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 | 23240 |
| CM0952A-II-h : mitoxantrone + Cytarabine | MEDICAL ONCOLOGY | 10280 | 10280 | 10280 | 10280 | 10280 | 10280 | 10280 | 10280 |
| CM0952A-II-i : Cytarabine | MEDICAL ONCOLOGY | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 | 6800 |
| CM0952A-II-j : Decitabine | MEDICAL ONCOLOGY | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 |
| CM0952A-II-k : azacytidine | MEDICAL ONCOLOGY | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 |
| CM0952A-II-l : Hydroxyurea | MEDICAL ONCOLOGY | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 | 1600 |
| CM0952A-II-m : Cytarabine - High Dose | MEDICAL ONCOLOGY | 9720 | 9720 | 9720 | 9720 | 9720 | 9720 | 9720 | 9720 |
| CM0952A-II-n : Cladribine + Cytarabine + Idarubicin + Gcsf | MEDICAL ONCOLOGY | 85150 | 85150 | 85150 | 85150 | 85150 | 85150 | 85150 | 85150 |
| CM0952A-II-o : Cladribine + Cytarabine + Mitoxantrone + Gcsf | MEDICAL ONCOLOGY | 40690 | 40690 | 40690 | 40690 | 40690 | 40690 | 40690 | 40690 |
| CM0952A-II-p : Fludarabine + Cytarabine + Idarubicin + Gcsf | MEDICAL ONCOLOGY | 66710 | 66710 | 66710 | 66710 | 66710 | 66710 | 66710 | 66710 |
| CM0952A-II-q : Etoposide +Cytarabine+Mitoxantrone | MEDICAL ONCOLOGY | 13260 | 13260 | 13260 | 13260 | 13260 | 13260 | 13260 | 13260 |
| CM0952A-II-r : Cytarabine SC | MEDICAL ONCOLOGY | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 | 2800 |
| CM0952A-II-s : azacytidine | MEDICAL ONCOLOGY | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 | 77500 |
| CM0952A-II-t : Decitabine | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
| CM0952A-II-u : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-III : Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-III-a-i : Rituximab + chlorambucil Cycle 1 | MEDICAL ONCOLOGY | 1084 | 1084 | 1084 | 1084 | 1084 | 1084 | 1084 | 1084 |
| CM0952A-III-a-ii : Rituximab + chlorambucil Cycle 3 | MEDICAL ONCOLOGY | 25584 | 25584 | 25584 | 25584 | 25584 | 25584 | 25584 | 25584 |
| CM0952A-III-a-iii : Rituximab + chlorambucil Cycle 4-8 | MEDICAL ONCOLOGY | 32984 | 32984 | 32984 | 32984 | 32984 | 32984 | 32984 | 32984 |
| CM0952A-III-a-iv : Maintanance - Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
| CM0952A-III-b : Rituximab Day 1, 8, 15, and 22: | MEDICAL ONCOLOGY | 100500 | 100500 | 100500 | 100500 | 100500 | 100500 | 100500 | 100500 |
| CM0952A-III-c : Chlorambucil | MEDICAL ONCOLOGY | 2344 | 2344 | 2344 | 2344 | 2344 | 2344 | 2344 | 2344 |
| CM0952A-III-d-i : Bendamustine + Rituximab (Cycle -1) | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
| CM0952A-III-d-ii : Bendamustine + Rituximab (Cycles 2-6) | MEDICAL ONCOLOGY | 37900 | 37900 | 37900 | 37900 | 37900 | 37900 | 37900 | 37900 |
| CM0952A-III-d-iii : Bendamustine (70mg) (Cycle -1) | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
| CM0952A-III-d-iv : Bendamustine (90 mg) (Cycles 2-6) | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0952A-III-e : Fludarabine + cyclophosphamide + rituximab (FCR) | MEDICAL ONCOLOGY | 31898 | 31898 | 31898 | 31898 | 31898 | 31898 | 31898 | 31898 |
| CM0952A-III-f : Fludarabine + rituximab (FR) | MEDICAL ONCOLOGY | 67930 | 67930 | 67930 | 67930 | 67930 | 67930 | 67930 | 67930 |
| CM0952A-III-g : Alemtuzumab + rituximab | MEDICAL ONCOLOGY | 108950 | 108950 | 108950 | 108950 | 108950 | 108950 | 108950 | 108950 |
| CM0952A-III-h : Alemtuzumab without rituximab | MEDICAL ONCOLOGY | 11450 | 11450 | 11450 | 11450 | 11450 | 11450 | 11450 | 11450 |
| CM0952A-III-i : High-dose methylprednisolone + rituximab | MEDICAL ONCOLOGY | 103955 | 103955 | 103955 | 103955 | 103955 | 103955 | 103955 | 103955 |
| CM0952A-III-j : High-dose methylprednisolone | MEDICAL ONCOLOGY | 6455 | 6455 | 6455 | 6455 | 6455 | 6455 | 6455 | 6455 |
| CM0952A-III-k : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-IV : Acute Lymphoblastic Leukemia (ALL) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-IV-i : Ph(+) AYA (Age 15-39 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-IV-i-a-1 : Childrens Oncology Group (COG) AALL-0031 INDUCTION PHASE | MEDICAL ONCOLOGY | 13340 | 13340 | 13340 | 13340 | 13340 | 13340 | 13340 | 13340 |
| CM0952A-IV-i-a-2 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 | MEDICAL ONCOLOGY | 17095 | 17095 | 17095 | 17095 | 17095 | 17095 | 17095 | 17095 |
| CM0952A-IV-i-a-3 : Childrens Oncology Group (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 | MEDICAL ONCOLOGY | 19175 | 19175 | 19175 | 19175 | 19175 | 19175 | 19175 | 19175 |
| CM0952A-IV-i-a-4 : Childrens Oncology Group (COG) AALL-0031 REINDUCTION | MEDICAL ONCOLOGY | 25291 | 25291 | 25291 | 25291 | 25291 | 25291 | 25291 | 25291 |
| CM0952A-IV-i-a-5 : Childrens Oncology Group (COG) AALL-0031 INTENSIFICATION | MEDICAL ONCOLOGY | 41425 | 41425 | 41425 | 41425 | 41425 | 41425 | 41425 | 41425 |
| CM0952A-IV-i-a-6 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 1-4 (8 weeks) | MEDICAL ONCOLOGY | 35621 | 35621 | 35621 | 35621 | 35621 | 35621 | 35621 | 35621 |
| CM0952A-IV-i-a-7 : Childrens Oncology Group (COG) AALL-0031 MAINTENANCE Cycles 5-12 (8 weeks) | MEDICAL ONCOLOGY | 12836 | 12836 | 12836 | 12836 | 12836 | 12836 | 12836 | 12836 |
| CM0952A-IV-i-b-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
| CM0952A-IV-i-b-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 |
| CM0952A-IV-i-b-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 |
| CM0952A-IV-i-b-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 |
| CM0952A-IV-i-b-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II | MEDICAL ONCOLOGY | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 |
| CM0952A-IV-i-b-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III | MEDICAL ONCOLOGY | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 |
| CM0952A-IV-i-b-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance | MEDICAL ONCOLOGY | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 |
| CM0952A-IV-i-c-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE | MEDICAL ONCOLOGY | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 |
| CM0952A-IV-i-c-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I | MEDICAL ONCOLOGY | 8460 | 8460 | 8460 | 8460 | 8460 | 8460 | 8460 | 8460 |
| CM0952A-IV-i-c-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II | MEDICAL ONCOLOGY | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 | 3700 |
| CM0952A-IV-i-c-4 : Multiagent Chemotherapy + TKIs MAINTENANCE | MEDICAL ONCOLOGY | 3410 | 3410 | 3410 | 3410 | 3410 | 3410 | 3410 | 3410 |
| CM0952A-IV-i-c-5 : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
| CM0952A-IV-i-c-6 : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
| CM0952A-IV-i-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-IV-ii : Ph(+) AYA (Age > 40 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-IV-ii-a-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
| CM0952A-IV-ii-a-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 | 62380 |
| CM0952A-IV-ii-a-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 | 11469 |
| CM0952A-IV-ii-a-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 | 13420 |
| CM0952A-IV-ii-a-5 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction II | MEDICAL ONCOLOGY | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 | 15133 |
| CM0952A-IV-ii-a-6 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Induction III | MEDICAL ONCOLOGY | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 | 5535 |
| CM0952A-IV-ii-a-7 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) Maintenance | MEDICAL ONCOLOGY | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 | 9923 |
| CM0952A-IV-ii-b-1 : Multiagent Chemotherapy + TKIs INDUCTION PHASE | MEDICAL ONCOLOGY | 15573 | 15573 | 15573 | 15573 | 15573 | 15573 | 15573 | 15573 |
| CM0952A-IV-ii-b-2 : Multiagent Chemotherapy + TKIs CONSOLIDATION I | MEDICAL ONCOLOGY | 12110 | 12110 | 12110 | 12110 | 12110 | 12110 | 12110 | 12110 |
| CM0952A-IV-ii-b-3 : Multiagent Chemotherapy + TKIs CONSOLIDATION II | MEDICAL ONCOLOGY | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 | 3200 |
| CM0952A-IV-ii-b-4 : Multiagent Chemotherapy + TKIs MAINTENANCE | MEDICAL ONCOLOGY | 6410 | 6410 | 6410 | 6410 | 6410 | 6410 | 6410 | 6410 |
| CM0952A-IV-ii-b-5 : Imatinib | MEDICAL ONCOLOGY | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 | 1525 |
| CM0952A-IV-ii-b-6 : Nilotinib | MEDICAL ONCOLOGY | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 | 17800 |
| CM0952A-IV-ii-c : Corticosteroids + TKIs | MEDICAL ONCOLOGY | 9035 | 9035 | 9035 | 9035 | 9035 | 9035 | 9035 | 9035 |
| CM0952A-IV-ii-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-IV-iii : Ph(-) AYA (Age 15-39 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-IV-iii-a-1 : GRAALL-2003 INDUCTION | MEDICAL ONCOLOGY | 15678 | 15678 | 15678 | 15678 | 15678 | 15678 | 15678 | 15678 |
| CM0952A-IV-iii-a-2 : GRAALL-2003 SALVAGE | MEDICAL ONCOLOGY | 28760 | 28760 | 28760 | 28760 | 28760 | 28760 | 28760 | 28760 |
| CM0952A-IV-iii-a-3 : GRAALL-2003 CONSOLIDATION | MEDICAL ONCOLOGY | 30779 | 30779 | 30779 | 30779 | 30779 | 30779 | 30779 | 30779 |
| CM0952A-IV-iii-a-4 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in complete remission [CR] after the first induction course) | MEDICAL ONCOLOGY | 15495 | 15495 | 15495 | 15495 | 15495 | 15495 | 15495 | 15495 |
| CM0952A-IV-iii-a-5 : GRAALL-2003 Late intensification between consolidation blocks 6 and 7 (for patients in CR after salvage course) | MEDICAL ONCOLOGY | 27210 | 27210 | 27210 | 27210 | 27210 | 27210 | 27210 | 27210 |
| CM0952A-IV-iii-a-6 : GRAALL-2003 Maintenance | MEDICAL ONCOLOGY | 56898 | 56898 | 56898 | 56898 | 56898 | 56898 | 56898 | 56898 |
| CM0952A-IV-iii-b : CNS Therapy-Treatment of patients with initial CNS involvement: | MEDICAL ONCOLOGY | 21155 | 21155 | 21155 | 21155 | 21155 | 21155 | 21155 | 21155 |
| CM0952A-IV-iii-v : CCG-1961 | MEDICAL ONCOLOGY | 18310 | 18310 | 18310 | 18310 | 18310 | 18310 | 18310 | 18310 |
| CM0952A-IV-iii-vi : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-IV-iv : Ph(-) AYA (Age > 40 years) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0952A-IV-iv-a-1 : CALGB 8811 (Larson Regimen) INDUCTION | MEDICAL ONCOLOGY | 18038 | 18038 | 18038 | 18038 | 18038 | 18038 | 18038 | 18038 |
| CM0952A-IV-iv-a-2 : CALGB 8811 (Larson Regimen) CONSOLIDATION | MEDICAL ONCOLOGY | 16685 | 16685 | 16685 | 16685 | 16685 | 16685 | 16685 | 16685 |
| CM0952A-IV-iv-b-1 : Hyper-CVAD with or without Rituximab CYCLE 1,3,5,7 | MEDICAL ONCOLOGY | 60970 | 60970 | 60970 | 60970 | 60970 | 60970 | 60970 | 60970 |
| CM0952A-IV-iv-b-2 : Hyper-CVAD with or without Rituximab CYCLE 2,4,6,8 | MEDICAL ONCOLOGY | 56820 | 56820 | 56820 | 56820 | 56820 | 56820 | 56820 | 56820 |
| CM0952A-IV-iii-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A : All Lymphoma Chemotheraphy | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-I : Hodgkins Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-I-a : ABVD | MEDICAL ONCOLOGY | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 |
| CM0953A-I-b : Escalated BEACOPP | MEDICAL ONCOLOGY | 7119 | 7119 | 7119 | 7119 | 7119 | 7119 | 7119 | 7119 |
| CM0953A-I-c : ABVD + Rituximab (cyled every 4 weeks) | MEDICAL ONCOLOGY | 28480 | 28480 | 28480 | 28480 | 28480 | 28480 | 28480 | 28480 |
| CM0953A-I-d-i : ABVD + Rituximab (1 cycle - weekly rituximab 4 doses) followed by ABVD | MEDICAL ONCOLOGY | 102480 | 102480 | 102480 | 102480 | 102480 | 102480 | 102480 | 102480 |
| CM0953A-I-d-ii : ABVD | MEDICAL ONCOLOGY | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 | 4480 |
| CM0953A-I-e-i : CHOP + Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
| CM0953A-I-e-ii : CHOP | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
| CM0953A-I-f-i : CVP +/- Rituximab | MEDICAL ONCOLOGY | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 |
| CM0953A-I-f-ii : CVP | MEDICAL ONCOLOGY | 1768 | 1768 | 1768 | 1768 | 1768 | 1768 | 1768 | 1768 |
| CM0953A-I-g : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
| CM0953A-I-h : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-II : Waldenstrom's Macroglobulinemia/ Lymphoplasmacytic Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-II-a : Bortezomib + dexamethasone | MEDICAL ONCOLOGY | 68038 | 68038 | 68038 | 68038 | 68038 | 68038 | 68038 | 68038 |
| CM0953A-II-b : Cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
| CM0953A-II-c : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
| CM0953A-II-d : Rituximab + cyclophosphamide + prednisone | MEDICAL ONCOLOGY | 25738 | 25738 | 25738 | 25738 | 25738 | 25738 | 25738 | 25738 |
| CM0953A-II-e : Rituximab + cyclophosphamide + dexamethasone | MEDICAL ONCOLOGY | 25520 | 25520 | 25520 | 25520 | 25520 | 25520 | 25520 | 25520 |
| CM0953A-II-f-i : Thalidomide with or without rituximab (Weeks 1 and 2) | MEDICAL ONCOLOGY | 2540 | 2540 | 2540 | 2540 | 2540 | 2540 | 2540 | 2540 |
| CM0953A-II-f-ii : Thalidomide with or without rituximab (Weeks 3-50) | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0953A-II-f-iii : Thalidomide with or without rituximab (Weeks 50-52) | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0953A-II-f-iv : Thalidomide with or without rituximab Weeks 2-5 and 13-16 | MEDICAL ONCOLOGY | 24000 | 24000 | 24000 | 24000 | 24000 | 24000 | 24000 | 24000 |
| CM0953A-II-g-i : Bendamustine with or without rituximab | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
| CM0953A-II-g-ii : Bendamustine - rituximab | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
| CM0953A-II-h-i : Cladribine with or without rituximab | MEDICAL ONCOLOGY | 32250 | 32250 | 32250 | 32250 | 32250 | 32250 | 32250 | 32250 |
| CM0953A-II-h-ii : Cladribine - rituximab | MEDICAL ONCOLOGY | 8250 | 8250 | 8250 | 8250 | 8250 | 8250 | 8250 | 8250 |
| CM0953A-II-i : Bendamustine | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
| CM0953A-II-j : Chlorambucil | MEDICAL ONCOLOGY | 1126 | 1126 | 1126 | 1126 | 1126 | 1126 | 1126 | 1126 |
| CM0953A-II-k : Fludarabine | MEDICAL ONCOLOGY | 12030 | 12030 | 12030 | 12030 | 12030 | 12030 | 12030 | 12030 |
| CM0953A-II-l : Fludarabine + cyclophosphamide + rituximab (FCR) | MEDICAL ONCOLOGY | 32398 | 32398 | 32398 | 32398 | 32398 | 32398 | 32398 | 32398 |
| CM0953A-II-m : Alemtuzumab | MEDICAL ONCOLOGY | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 | 2650 |
| CM0953A-II-n : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III : NON HODGKINS LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-i : BURKITT LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-i-a -1 : CALGB 10002 Cycle 1: | MEDICAL ONCOLOGY | 8967 | 8967 | 8967 | 8967 | 8967 | 8967 | 8967 | 8967 |
| CM0953A-III-i-a-2 : CALGB 10002 Cycles 2 (beginning Day 8), 4, and 6: | MEDICAL ONCOLOGY | 66113 | 66113 | 66113 | 66113 | 66113 | 66113 | 66113 | 66113 |
| CM0953A-III-i-a-3 : CALGB 10002 Cycles 3, 5, and 7: | MEDICAL ONCOLOGY | 33108 | 33108 | 33108 | 33108 | 33108 | 33108 | 33108 | 33108 |
| CM0953A-III-i-a-4 : CALGB 10002 Cycles 4, and 6: | MEDICAL ONCOLOGY | 36413 | 36413 | 36413 | 36413 | 36413 | 36413 | 36413 | 36413 |
| CM0953A-III-i-b : CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine with intrathecal MTX + cytarabine, followed by systemic MTX and cytarabine) with or without Rituximab | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
| CM0953A-III-i-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1 & 2) | MEDICAL ONCOLOGY | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 |
| CM0953A-III-i-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | MEDICAL ONCOLOGY | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 |
| CM0953A-III-i-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
| CM0953A-III-i-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 |
| CM0953A-III-i-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 |
| CM0953A-III-i-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 |
| CM0953A-III-i-e-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
| CM0953A-III-i-e-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M (original or modified) (cyclophosphamide + doxorubicin + vincristine, plus intrathecal MTX + cytarabine, followed by systemic MTX) alternating with IVAC (ifosfamide + cytarabine + etoposide) and intrathecal MTX with or without Rituximab | MEDICAL ONCOLOGY | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 |
| CM0953A-III-i-f : RICE (rituximab + ifosfamide + carboplatin + etoposide) | MEDICAL ONCOLOGY | 32994 | 32994 | 32994 | 32994 | 32994 | 32994 | 32994 | 32994 |
| CM0953A-III-i-g : RIVAC (rituximab + ifosfamide + cytarabine + etoposide) | MEDICAL ONCOLOGY | 43894 | 43894 | 43894 | 43894 | 43894 | 43894 | 43894 | 43894 |
| CM0953A-III-i-h : RGDP (rituximab + gemcitabine + dexamethasone + cisplatin) | MEDICAL ONCOLOGY | 32255 | 32255 | 32255 | 32255 | 32255 | 32255 | 32255 | 32255 |
| CM0953A-III-i-i : HDAC + Rituximab | MEDICAL ONCOLOGY | 27800 | 27800 | 27800 | 27800 | 27800 | 27800 | 27800 | 27800 |
| CM0953A-III-i-ii : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III-ii : NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-ii-a-1 : Zidovudine + alpha-interferon (induction) | MEDICAL ONCOLOGY | 4580 | 4580 | 4580 | 4580 | 4580 | 4580 | 4580 | 4580 |
| CM0953A-III-ii-a-2 : Zidovudine + alpha-interferon (Maintenance Therapy) | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0953A-III-ii-b : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
| CM0953A-III-ii-c : CHOEP | MEDICAL ONCOLOGY | 8640 | 8640 | 8640 | 8640 | 8640 | 8640 | 8640 | 8640 |
| CM0953A-III-ii-d : Dose-adjusted EPOCH(etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) | MEDICAL ONCOLOGY | 6892 | 6892 | 6892 | 6892 | 6892 | 6892 | 6892 | 6892 |
| CM0953A-III-ii-e : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III-iii : DIFFUSE LARGE B CELL LYMPHOMA | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-iii-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
| CM0953A-III-iii-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
| CM0953A-III-iii-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 |
| CM0953A-III-iii-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) | MEDICAL ONCOLOGY | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 |
| CM0953A-III-iii-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | MEDICAL ONCOLOGY | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 |
| CM0953A-III-iii-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
| CM0953A-III-iii-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 |
| CM0953A-III-iii-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 |
| CM0953A-III-iii-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 |
| CM0953A-III-iii-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
| CM0953A-III-iii-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
| CM0953A-III-iii-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III-iv : AIDS-Related B-Cell Lymphomas | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-iv-a : CDE (cyclophosphamide + doxorubicin + etoposide) + rituximab | MEDICAL ONCOLOGY | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 | 2500 |
| CM0953A-III-iv-b-1 : CODOX-M alternated with IVAC (CODOX-M) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 | 46780 |
| CM0953A-III-iv-b-2 : CODOX-M alternated with IVAC (IVAC) CODOX-M/IVAC (modified) (cyclophosphamide + vincristine + doxorubicin + high-dose methotrexate alternating with ifosfamide + etoposide + high-dose cytarabine) | MEDICAL ONCOLOGY | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 | 42847 |
| CM0953A-III-iv-c-1 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 1&2) | MEDICAL ONCOLOGY | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 | 32972 |
| CM0953A-III-iv-c-2 : Dose-adjusted EPOCH (etoposide + prednisone + vincristine + cyclophosphamide + doxorubicin) + intrathecal MTX + rituximab (Cycles 3-6) | MEDICAL ONCOLOGY | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 | 32572 |
| CM0953A-III-iv-d-1 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 1 and 3) | MEDICAL ONCOLOGY | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 | 59429 |
| CM0953A-III-iv-d-2 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 2 and 4) | MEDICAL ONCOLOGY | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 | 61880 |
| CM0953A-III-iv-d-3 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 5 & 7) | MEDICAL ONCOLOGY | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 | 10969 |
| CM0953A-III-iv-d-4 : HyperCVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone alternating with high-dose methotrexate and cytarabine) (Cycles 6 & 8) | MEDICAL ONCOLOGY | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 | 12920 |
| CM0953A-III-iv-e-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
| CM0953A-III-iv-e-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
| CM0953A-III-iv-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III-v : Primary Cutaneous Marginal Zone or Follicle Center Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-v-a-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
| CM0953A-III-v-a-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
| CM0953A-III-v-b : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
| CM0953A-III-v-c : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III-vi : Follicular Lymphoma (Grade 1-2) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-vi-a-1 : Bendamustine with or without rituximab | MEDICAL ONCOLOGY | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 | 36500 |
| CM0953A-III-vi-a-2 : Bendamustine (-) rituximab | MEDICAL ONCOLOGY | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 | 12500 |
| CM0953A-III-vi-b-1 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) with or without Rituximab | MEDICAL ONCOLOGY | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 | 26818 |
| CM0953A-III-vi-b-2 : Cyclophosphamide + Doxorubicin + Vincristine + Prednisone (CHOP) | MEDICAL ONCOLOGY | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 | 2818 |
| CM0953A-III-vi-c : Cyclophosphamide + Vincristine + Prednisone + Rituximab (RCVP) | MEDICAL ONCOLOGY | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 | 25768 |
| CM0953A-III-vi-d : Rituximab | MEDICAL ONCOLOGY | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 | 25500 |
| CM0953A-III-vi-e : Lenalidomide + Rituximab | MEDICAL ONCOLOGY | 4940 | 4940 | 4940 | 4940 | 4940 | 4940 | 4940 | 4940 |
| CM0953A-III-vi-f : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0953A-III-vii : Extranodal NK/T-Cell Lymphoma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0953A-III-vii-a : SMILE | MEDICAL ONCOLOGY | 27483 | 27483 | 27483 | 27483 | 27483 | 27483 | 27483 | 27483 |
| CM0953A-III-vii-b : DeVIC +RT | MEDICAL ONCOLOGY | 9163 | 9163 | 9163 | 9163 | 9163 | 9163 | 9163 | 9163 |
| CM0953A-III-vii-c : VIPID | MEDICAL ONCOLOGY | 6619 | 6619 | 6619 | 6619 | 6619 | 6619 | 6619 | 6619 |
| CM0953A-III-vii-d : Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0954 : Myelodysplastic Syndromes Treatment Regimens | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0954-i : Symptomatic Anemia With del(5q) with or without Other Cytogenetic Abnormalities | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0954-i-a : Lenalidomide | MEDICAL ONCOLOGY | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 |
| CM0954-ii : Symptomatic Anemia Without del(5q) and Serum Erythropoietin =500mU/mL | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0954-ii-a-1 : rHu-Epo with or without G-CSF | MEDICAL ONCOLOGY | 26080 | 26080 | 26080 | 26080 | 26080 | 26080 | 26080 | 26080 |
| CM0954-ii-a-2 : rHu-Epo (-) G-CSF | MEDICAL ONCOLOGY | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 | 25750 |
| CM0954-ii-b-1 : Darbepoetin alfa with or without G-CSF | MEDICAL ONCOLOGY | 9330 | 9330 | 9330 | 9330 | 9330 | 9330 | 9330 | 9330 |
| CM0954-ii-b-2 : Darbepoetin alfa (-) G-CSF | MEDICAL ONCOLOGY | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 | 9000 |
| CM0954-iii : Symptomatic Anemia Without del(5q), Serum Erythropoietin >500mU/mL, Unlikely to Respond to IST | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0954-iii-a-1 : Decitabine (15mg/m2) | MEDICAL ONCOLOGY | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 | 15500 |
| CM0954-iii-a-2 : Decitabine (20mg/m2) | MEDICAL ONCOLOGY | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 | 16500 |
| CM0954-iii-b : Lenalidomide | MEDICAL ONCOLOGY | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 |
| CM0955 : Multiple Myeloma | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0955-a : Lenalidomide (28 days) + Dexamethasone | MEDICAL ONCOLOGY | 6817 | 6817 | 6817 | 6817 | 6817 | 6817 | 6817 | 6817 |
| CM0955-b : Lenalidomide (21 days) + Dexamethasone | MEDICAL ONCOLOGY | 5004 | 5004 | 5004 | 5004 | 5004 | 5004 | 5004 | 5004 |
| CM0955-c : Lenalidomide | MEDICAL ONCOLOGY | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 | 2575 |
| CM0955-d : Bendamustine + Lenalidomide + Dexamethasone | MEDICAL ONCOLOGY | 13639 | 13639 | 13639 | 13639 | 13639 | 13639 | 13639 | 13639 |
| CM0955-e : Bendamustine | MEDICAL ONCOLOGY | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 | 22000 |
| CM0955-f : Cyclophosphamide + Lenalidomide + Dexamethasone | MEDICAL ONCOLOGY | 5136 | 5136 | 5136 | 5136 | 5136 | 5136 | 5136 | 5136 |
| CM0955-g : Dexamethasone + Cyclophosphamide + Etoposide + Cisplatin (DCEP) | MEDICAL ONCOLOGY | 5764 | 5764 | 5764 | 5764 | 5764 | 5764 | 5764 | 5764 |
| CM0955-h : Dexamethasone + Thalidomide + Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide (DT-PACE) | MEDICAL ONCOLOGY | 7724 | 7724 | 7724 | 7724 | 7724 | 7724 | 7724 | 7724 |
| CM0955-i : High-dose Cyclophosphamide | MEDICAL ONCOLOGY | 5140 | 5140 | 5140 | 5140 | 5140 | 5140 | 5140 | 5140 |
| CM0955-j : VAD / VAMP | MEDICAL ONCOLOGY | 6104 | 6104 | 6104 | 6104 | 6104 | 6104 | 6104 | 6104 |
| CM0955-k : Melphalan | MEDICAL ONCOLOGY | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 | 3900 |
| CM0955-l : Melphalan + Prednisolone | MEDICAL ONCOLOGY | 1137 | 1137 | 1137 | 1137 | 1137 | 1137 | 1137 | 1137 |
| CM0955-m : Thalidomide + Dexamethasone | MEDICAL ONCOLOGY | 2376 | 2376 | 2376 | 2376 | 2376 | 2376 | 2376 | 2376 |
| CM0955-n : Melphalan / Prednisolone/Thalidomide(MPT) | MEDICAL ONCOLOGY | 2257 | 2257 | 2257 | 2257 | 2257 | 2257 | 2257 | 2257 |
| CM0956 : ALL LYMPHOMA SALVAGE CHEMO (Package 953 to be utilised) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0957 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (Package 953 to be utilised) | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0100-N : BREAST CANCER - TAMOXIFEN | MEDICAL ONCOLOGY | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CM0100-O : BREAST CANCER - AROMATASE INHIBITORS | MEDICAL ONCOLOGY | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 | 1000 |
| CM0100-P : BREAST CANCER - Zoledronic Acid for skeletal metastasis | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
| CM0124-c : PROSTATE CANCER - Zoledronic Acid for skeletal metastasis | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
| CM0955-O : Multiple Myeloma - Zoledronic Acid | MEDICAL ONCOLOGY | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 | 2700 |
| CM0100-a-III : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 175mg/m2) Repeat cycle - every 21 days for 4 cycles | MEDICAL ONCOLOGY | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 | 7000 |
| CM0100-a-IV : BREAST CANCER - Paclitaxel (Preceeded by Dose Dense AC - 4 cycles) ; (Day 1: Paclitaxel 80mg/m2) Repeat cycle - weekly for 12 cycles | MEDICAL ONCOLOGY | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 | 3500 |
| CM0101-a-IV : BLADDER CANCER - Radiosensitizing - Cisplatinc + 5-FU ; Days 1, 2, 3, 15, 16, and 17: IV hydration at a rate of 500mL/hour; followed by 5-FU 400mg/m2 IV push; followed by cisplatin 15mg/m2 IV over 1 hour as induction and consolidation therapy | MEDICAL ONCOLOGY | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 | 9800 |
| CM0101-a-V : BLADDER CANCER -Radiosensitizing - Cisplatin + paclitaxel ; Days 1, 8, and 15: Paclitaxel 50mg/m2 ; Day 1-3, 8-10, 15-17: Cisplatin 15mg/m2; followed by twice-daily radiotherapy for 8 days | MEDICAL ONCOLOGY | 18400 | 18400 | 18400 | 18400 | 18400 | 18400 | 18400 | 18400 |
| CM0101-a-VI : BLADDER CANCER -Radiosensitizing - 5-FU + mitomycin32 ; Day 1 of radiotherapy: Mitomycin 12mg/m2 IV bolus, plus ; Week 1 (fractions 1-5) and Week 4 (fractions 16-20) of radiotherapy: 5-FU 500mg/m2 continuous IV infusion (10 days total) | MEDICAL ONCOLOGY | 15100 | 15100 | 15100 | 15100 | 15100 | 15100 | 15100 | 15100 |
| CM0101-c : BLADDER CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0103 : OESOPHAGEAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0103-v: ESOPHAGEAL CANCER - Concurrent Cisplatin; Cisplatin 40mg/m2 IV once weekly for up to 5 cycles | MEDICAL ONCOLOGY | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 | 1800 |
| CM0105 : COLORECTAL CANCER | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0106 : OSTEOSARCOMA/ BONE TUMORS | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0106-vi : Other bone tumors - Mesenchymal Chordosarcoma VIDE (vincristine + ifosfamide + doxorubicin + etoposide) ; Day 1: Vincristine 1.4mg/m2 (max 2mg), ; Days 1-3: Doxorubicin 20mg/m2 IV + ifosfamide 3mg/m2 IV + mesna 3g/m2 + etoposide 150mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. | MEDICAL ONCOLOGY | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 | 9200 |
| CM0110 : Neuroblastoma ALL STAGES | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM0114-i-b-1 : EWINGS SARCOMA - Induction Treatment - VAC/IE - VAC ; Day 1: Vincristine 2mg/m2 (max 2mg) IV, doxorubicin 75mg/m2 IV bolus, cyclophosphamide 1,200mg/m2 IV, mesna. ; Dactinomycin 1.25mg/m2 IV can be substituted for doxorubicin when a total doxorubicin dose of 375mg/m2 is reached. | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
| CM0114-i-b-2 : EWINGS SARCOMA - Induction Treatment - VAC/IE - IE ; IE cycles ; Days 1-5: Ifosfamide 1,800mg/m2 IV + mesna + etoposide 100mg/m2 IV. ; Repeat each cycle every 3 weeks for 17 cycles. | MEDICAL ONCOLOGY | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 | 6000 |
| CM0114-i-e : EWINGS SARCOMA - Induction Treatment - VACA ; Day 1: Vincristine 1.5mg/m2 IV + cyclophosphamide 1,200mg/m2 IV + mesna ; Days 1, 3, and 5: Dactinomycin 0.5mg/m2 IV ; Days 2 and 4: Doxorubicin 30mg/m2 IV. ; Repeat cycle every 21 days for 10 cycles. | MEDICAL ONCOLOGY | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 | 4600 |
| CM0117-e : VULVAL CANCER - Cisplatin + 5FU ; Days 1 and 29: Cisplatin 50mg/m2 IV ; Days 2-5, and 30-33: 5-FU 1,000mg/m2 IV | MEDICAL ONCOLOGY | 11100 | 11100 | 11100 | 11100 | 11100 | 11100 | 11100 | 11100 |
| CM0128-ii-c-1 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - Concurrent Temozolomide (with RT) - followed by adjuvant temozolomide ; Daily oral temozolomide (75mg/m2/day, 7 days per week from the first to the last day of radiotherapy) | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
| CM0128-ii-c-2 : BRAIN CARCINOMA - Systemic Therapy for Anaplastic Gliomas - adjuvant temozolomide - preceeded by Concurrent Temozolomide (with RT) ; Temozolomide 150-200mg/m2/day for 5 days. ; Repeat cycle every 28 days for 6 cycles | MEDICAL ONCOLOGY | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 | 2100 |
| CM0130 I a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily | MEDICAL ONCOLOGY | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 |
| CM0130 I b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. | MEDICAL ONCOLOGY | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 |
| CM0130 I c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Bevacizumab + IFN-alpha ; Bevacizumab 10mg/kg IV every 2 weeks + IFN-alpha. | MEDICAL ONCOLOGY | 66750 | 66750 | 66750 | 66750 | 66750 | 66750 | 66750 | 66750 |
| CM0130 I d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - First-line Therapy for Patients with Predominantly Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily | MEDICAL ONCOLOGY | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 |
| CM0130 II a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Everolimus ; Everolimus 10mg orally once daily | MEDICAL ONCOLOGY | 37250 | 37250 | 37250 | 37250 | 37250 | 37250 | 37250 | 37250 |
| CM0130 II b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Pazopanib ; Pazopanib 800mg orally once daily | MEDICAL ONCOLOGY | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 |
| CM0130 II c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sorafenib ; Sorafenib 400mg orally twice daily | MEDICAL ONCOLOGY | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 |
| CM0130 II d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. | MEDICAL ONCOLOGY | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 |
| CM0130 II e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Subsequent Therapy for Patients with Predominantly Clear Cell Carcinoma - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. | MEDICAL ONCOLOGY | 66250 | 66250 | 66250 | 66250 | 66250 | 66250 | 66250 | 66250 |
| CM0130 III a : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sunitinib ; Sunitinib 50mg orally daily for 4 weeks, followed by 2 weeks off. | MEDICAL ONCOLOGY | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 | 29250 |
| CM0130 III b : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Bevacizumab ; Bevacizumab 10mg/kg IV every 2 weeks. | MEDICAL ONCOLOGY | 66250 | 66250 | 66250 | 66250 | 66250 | 66250 | 66250 | 66250 |
| CM0130 III c : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Everolimus ; Everolimus 10mg orally once daily | MEDICAL ONCOLOGY | 37250 | 37250 | 37250 | 37250 | 37250 | 37250 | 37250 | 37250 |
| CM0130 III d : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Erlotinib ; Erlotinib 150mg orally once daily | MEDICAL ONCOLOGY | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 | 3400 |
| CM0130 III e : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Pazopanib ; Pazopanib 800mg orally once daily | MEDICAL ONCOLOGY | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 | 19250 |
| CM0130 III f : RENAL CELL CARCINOMARENAL CELL CARCINOMA - Systemic Therapy for Patients with Non-Clear Cell Histology - Sorafenib ; Sorafenib 400mg orally twice daily | MEDICAL ONCOLOGY | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 | 3650 |
| CM0130 IV: RENAL CELL CARCINOMARENAL CELL CARCINOMA - Other Regimen (May be chosen for any other internationally approved Curative regimen with submission of substantiating Documents) | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0131-i-g : UNKNOWN PRIMARY - Adenocarcinoma - mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
| CM0131-i-h : UNKNOWN PRIMARY - Adenocarcinoma - CapeOX ; Day 1: Oxaliplatin 130mg/m2 IV over 2 hours ; Day 1-14: Capecitabine 850-1000mg/m2 orally twice daily. ; Repeat cycle every 3 weeks for 16 cycles. | MEDICAL ONCOLOGY | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 | 6500 |
| CM0131-i-i : UNKNOWN PRIMARY - Adenocarcinoma - Irinotecan + carboplatin ; Day 1: Carboplatin AUC 5mg per min/mL IV ; Days 1, 8, and 15: Irinotecan 60mg/m2 IV. ; Repeat cycle every 4 weeks for up to 6 cycles | MEDICAL ONCOLOGY | 7700 | 7700 | 7700 | 7700 | 7700 | 7700 | 7700 | 7700 |
| CM0131-ii-c : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + carboplatin ; Day 1: Carboplatin AUC 6mg per min/mL IV over 30 minutes + paclitaxel 200mg/m2 IV over 3 hours. ; Repeat cycle every 3 weeks for 8 cycles in responding patients and for 6 cycles maximum in patients with stable disease | MEDICAL ONCOLOGY | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 | 7200 |
| CM0131-ii-d : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + gemcitabine ; Day 1: Cisplatin 100mg/m2 IV ; Day 1 and 8: Gemcitabine 1250mg/m2 IV. ; Repeat every 3 weeks for 4 cycles. | MEDICAL ONCOLOGY | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 | 5250 |
| CM0131-ii-e : UNKNOWN PRIMARY - Squamous cell carcinoma -mFOLFOX ; Day 1: Oxaliplatin 85mg/m2 IV over 2 hours + leucovorin 400mg/m2 IV over 2 hours + 5-FU 400mg/m2 IV bolus then ; Days 1 and 2: 5-FU 1200mg/m2 (total 2400mg/m2 over 46-48 hours) IV continuous infusion. ; Repeat cycle every 2 weeks for 24 cycles. | MEDICAL ONCOLOGY | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 | 8000 |
| CM0131-ii-f : UNKNOWN PRIMARY - Squamous cell carcinoma -Paclitaxel + cisplatin ; Day 1: Paclitaxel 175mg/m2 IV + cisplatin 60mg/m2 IV. ; Repeat cycle every 3 weeks. | MEDICAL ONCOLOGY | 6450 | 6450 | 6450 | 6450 | 6450 | 6450 | 6450 | 6450 |
| CM0131-ii-g : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + carboplatin ; Day 1: Docetaxel 75mg/m2 IV over 30 minutes + carboplatin AUC 5mg per min/mL IV over 30 minutes. ; Repeat cycle every 3 weeks for 8 cycles | MEDICAL ONCOLOGY | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 | 8700 |
| CM0131-ii-h : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 60mg/m2 IV + cisplatin 80mg/m2 IV. ; Repeat cycle every 3 weeks for 2 cycles and an additional 4 cycles until disease progression is demonstrated | MEDICAL ONCOLOGY | 5040 | 5040 | 5040 | 5040 | 5040 | 5040 | 5040 | 5040 |
| CM0131-ii-i : UNKNOWN PRIMARY - Squamous cell carcinoma -Docetaxel + cisplatin ; Day 1: Docetaxel 75mg/m2 IV + cisplatin 75mg/m2 IV. ; Repeat cycle every 3 weeks for up to 6 cycles. | MEDICAL ONCOLOGY | 3820 | 3820 | 3820 | 3820 | 3820 | 3820 | 3820 | 3820 |
| CM0131-ii-j : UNKNOWN PRIMARY - Squamous cell carcinoma -Cisplatin + fluorouracil ; Days 1-5: Cisplatin 20mg/m2 IV ; Days 1-5: Fluorouracil 700mg/m2/day IV via continuous infusion over 24 hours. ; Repeat cycle every 4 weeks for 3 cycles. | MEDICAL ONCOLOGY | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 | 7050 |
| CM0952A-I-iii-j : Chronic Myeloid Leukemia (CML) - Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM0952A-II-z : Acute Myeloid Leukemia (AML) - Other Regimen | MEDICAL ONCOLOGY | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 | 10000 |
| CM1419 : Acute lymphoblastic leukemia: Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1420 : Acute myeloid leukemia: Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1421 : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1422 : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1423 : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1424 : Retinoblastoma (Intraocular): supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1425 : Retinoblastoma (extraocular): supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1426 : Brain tumors: supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1427 : Histiocytosis: supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1428 : Bone tumors/soft tissue sarcomas : supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1429 : Chronic Myeloid Leukemia : supportive care/ rehabilitation | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1430 : Terminally IllPalliative And Supportive Therapy - Per month | MEDICAL ONCOLOGY | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 |
| CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage | MEDICAL ONCOLOGY | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 | 30000 |
| CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 15000 | 15000 | 15000 | 15000 | 15000 | 15000 | 15000 | 15000 |
| CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 | 25000 |
| CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 50000 | 50000 | 50000 | 50000 | 50000 | 50000 | 50000 | 50000 |
| CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN | MEDICAL ONCOLOGY | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 | 20000 |
| CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month | MEDICAL ONCOLOGY | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 | 3000 |
The Project Director
Tamil Nadu Health Systems Project (TNHSP)
3rd Floor, DMS Annex New Building
259 Anna Salai, Teynampet
Chennai - 600 006, Tamil Nadu.
CMCHIS Project Office Chief Minister's Comprehensive Health Insurance Scheme
No.226,Om Sakthi Towers, Kilpauk Garden Road, Kilpauk, Chennai-600010, Tamil Nadu
Scan QR Code or
Click Here
to Download the Mobile app for Beneficiary